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Abstract: Background: Several clinical trials, as well as observational statistics, have exhib-
ited that the advantages of antiretroviral [ARV] treatment for humans with Human Immunode-
ficiency Virus / Acquired Immune Deficiency Syndrome HIV/AIDS exceed their risks. 
Therapeutic drug monitoring [TDM] plays a key role in optimization of ARV therapy. Deter-
mination of ARV’s in plasma, blood cells, and other biological matrices frequently requires 
separation techniques capable of high effectiveness, specific selectivity and high sensitivity. 
High-performance liquid chromatography [HPLC] coupled with ultraviolet [UV], Photodiode 
array detectors [PDA], Mass spectrophotometer [MS] detectors etc. are the important quantita-
tive techniques used for the estimation of pharmaceuticals in biological samples. 
Objective: This review article is aimed to give an extensive outline of different bio-analytical 
techniques which have been reported for direct quantitation of ARV’s. This article aimed to 
establish an efficient role played by the TDM in the optimum therapeutic outcome of the ARV 
treatment. It also focused on establishing the prominent role played by the separation tech-
niques like HPLC and UPLC along with the detectors like UV and Mass in TDM. 
Method: TDM is based on the principle that for certain drugs, a close relationship exists be-
tween the plasma level of the drug and its clinical effect. TDM is of no value if the relationship 
does not exist. The analytical methodology employed in TDM should: 1) distinguish similar 
compounds; 2) be sensitive and precise and 3) is easy to use  
Results: This review highlights the advancement of the chromatographic techniques beginning 
from the HPLC-UV to the more advanced technique like UPLC-MS/MS. TDM is essential to 
ensure adherence, observe viral resistance and to personalize ARV dose regimens. It is ob-
served that the analytical methods like immunoassays and liquid chromatography with detec-
tors like UV, PDA, Florescent, MS, MS/MS and Ultra performance liquid chromatography 
(UPLC)-MS/MS have immensely contributed to the clinical outcome of the ARV therapy. 
Assay methods are not only helping physicians in limiting the side effects and drug interac-
tions but also assisting in monitoring patient’s compliance. 
Conclusion: The present review revealed that HPLC has been the most widely used system 
irrespective of the availability of more sensitive chromatographic technique like UPLC. 
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INTRODUCTION 
 The idea of overseeing pharmacotherapy based 
on plasma drug concentration has been utilized for 
quite a long time in an assortment of clinical set-
tings. The curiosity in studying therapeutic drug 
monitoring [TDM] of ARV drugs has developed 
considerably since highly active ARV therapy 
[HAART] turned into a prime therapeutic inter-
vention of care in clinical practice [1, 2]. The 
drugs used in the treatment of HIV infection are 
known as ARV drugs and there are around 24 of 
them approved by the FDA. Although, the ARV 
drugs do not cure the patients, when taken in com-
bination, they can prevent the growth of the virus 
and further damage to the immune system. HIV 
attaches itself to the CDR5 receptor of the CD4 
immune cells and empties its contents inside the 
cell. Once inside the HIV, the enzyme called re-
verse transcriptase builds the HIV DNA on HIV 
RNA through the process called as reverse tran-
scription. HIV DNA then integrates with host 
chromosome using the HIV enzyme called as inte-
grase, thereby establishing the HIV infection in-
side the cell. HIV DNA segment in the host chro-
mosome is activated to produce the HIV proteins 
when infected cells reproduce. Later, all the HIV 
protein comes together to bud out of the cells as an 
immature virus. Protease enzyme then cuts the 
long polypeptide into small functional units to 
form the mature virus. Till date, ARV drugs have 
immensely contributed to increasing the life ex-
pectancy of the patient. Adherence to the dose re-
gime is the key to success of the ARV therapy [3]. 
However, irrespective of adherence to routine re-
gime and diet, bioavailability of the ARV drugs in 
HIV infected patients is significantly affected by 
the genetically determined difference in drug dis-
tribution and elimination. Various studies have 
already been established based on inter-individual 
variability in plasma concentrations of ARVs, 
lesser virological failure rates as well the adverse 
reactions that occur when optimal concentrations 
of ARV drugs are accomplished. Thus, TDM can 
help streamline ARV treatment [4]. 
 TDM of ARV drugs is not only the technique to 
study the drug-drug interactions but also is an im-
portant tool to optimize the therapy in routine 
clinical practice. Moreover, pieces of evidence are 
also available showing that inadequate plasma 
drug concentrations can favour the development of 
drug resistance mutations and imperil present and 
future treatment choices. Various clinical trials 
have shown that drug serum concentrations are an 
essential component for the advancement in re-
sponse to therapy for HIV [5]. The main goal of 
TDM of ARV drugs is to optimise treatment and 
its acceptability and to minimise drug-related tox-
icity and resistance. 
 Investigational studies in adults suggest that 
altered doses and regimen choices are primarily 
based on TDM accomplished via ARV drug con-
centrations which are related to optimal clinical 
response and/or acceptability [6-12]. The applica-
tion of TDM requires, however, the availability of 
feasible and reliable techniques. This review is 
focused on different bio-analytical methods devel-
oped on HPLC in conjugation with UV-PDA and 
Mass detectors. For this review, we have exten-
sively used all the important literature which dealt 
with the quantitative estimation and which con-
tributed immensely to the clinical outcome of the 
patients infected with HIV. 
ANALYTICAL TECHNIQUES IN TDM 
 As new drugs are constantly approved and in-
troduced in HAART regimen, the need for TDM is 
also growing. Chromatography coupled with vari-
ous spectrophotometry detectors such as UV, 
PDA, and MS is the instrument of choice of the 
most clinical pharmacology laboratories [13]. Al-
ternatively, immunoassays which are commer-
cially available for various drugs are also becom-
ing available for the TDM of ARVs [14]. 
Immunoassays in TDM 
 TDM of clinical agents and drugs of abuse test-
ing are accomplished by automated immunoassay 
techniques. Several immunoassays are also avail-
able for the quantitative estimation of the ARVs 
[15]. Most immunoassay techniques use samples 
without any prior treatment and analysed on fully 
computerized, random access systems. The immu-
noassays require a very small quantity of sample 
reagents [mostly <100µL], readily available in the 
instrument and concentration of unknown samples 
is extrapolated using calibration curves stored in 
the system. In immunoassays, the analyte is identi-
fied by its complexation with a particular binding 
molecule, which in maximum instances is an ana-
lyte-specific antibody [16]. These immunological 
reactions are further utilized to format and prepare 
various labels giving rise to the diverse arrays of 
immunoassays. On the basis of assay design, im-
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munoassays are classified as competition and im-
munometric [17]. Competition immunoassays are 
mostly used for analytes with small molecular 
weight and require single analyte-specific antibody 
whereas, immunometric immunoassays work bet-
ter for analytes with larger molecular weight [e.g. 
proteins or peptides] and use two distinct antibod-
ies [18]. 
High-Performance Liquid Chromatography 
[HPLC] 
 Although gas chromatography (GC) is used as a 
separation technique, its use is limited to volatile 
molecules. Liquid chromatography, on the other 
hand, can be used for separation of both polar and 
nonpolar molecules Unlike gas chromatography, 
derivatization of the analyte is not necessary for 
HPLC analysis [19]. On the basis of mode of sepa-
ration, HPLC is classified into two types’ viz., 
normal phase and reverse phase chromatography. 
In normal phase chromatography, the stationary 
phase is polar [hydrophilic] and the mobile phase 
is nonpolar [hydrophobic] whereas reverse phase 
chromatography is the inverse of this. Several de-
tectors can be used for checking peak elution from 
HPLC column including UV-Vis, PDA, refractive 
index detectors, mass spectrometer, conductivity 
detectors, fluorescence detectors, etc. In clinical 
laboratories, UV detection is most commonly pre-
ferred even though other detection techniques in-
cluding fluorescence and electrochemical methods 
are also available. 
Liquid Chromatography-Mass Spectrometry 
[LCMS] 
 LCMS is a modern analytical technique similar 
to gas chromatography (GC)-MS which finds its 
application in clinical toxicology laboratories for 
screening, detection and quantification of drugs of 
abuse in biological fluids. LCMS is widely used 
due to its high sensitivity and specificity. LCMS is 
preferred over GCMS as it enables analysis of po-
lar, charged and thermally labile compounds that 
require derivatization with GC. LCMS also has an 
advantage regarding its use in clinical toxicology 
laboratories for analysing very low concentration 
of drugs [ng/ml] in biological matrices and high 
molecular weight compounds [20]. In LCMS sys-
tem, the individual components in a mixture are 
first separated on the column, transferred to the 
ionization chamber and then moved to MS for 
fragmentation through an interface. Amongst the 
popular interfaces like electrospray ionization, 
atomic pressure chemical ionization, atomic pres-
sure photo-ionization, the former i.e. electrospray 
ionization is most commonly utilized in clinical 
laboratories. On the basis of mass/charge ratio, the 
ions are separated and analyzed by MS to give a 
mass spectrum. The major types of mass spectro-
metric analyzers are quadrupole analyser, ion trap 
analysers, time-of-flight analyser and hybrid 
analysers [21-23]. 
Ultra-Performance Liquid Chromatography 
[UPLC] 
 UPLC is an advanced version of HPLC with the 
same working principle but with enhanced resolu-
tion, speed and sensitivity for the detection of 
drugs. The key focus of this technology is to de-
liver the mobile phase at high pressure [about 
15,000 psi] and column packing with the smaller 
particle size [1.7-1.8 µm]. The key advantages of 
UPLC include lesser runtime, reduced operation 
cost and less solvent consumption. 
 The principle of UPLC is based on Van Deem-
ter equation that describes the connection between 
linear velocity [flow rate] and plate height [HETP 
i.e. Height Equivalent to the Theoretical Plate or 
column efficiency] [24]. As one of the variables is 
microparticle size, the efficiency of UPLC does 
not reduce at increased flow rates. UPLC is widely 
accepted in clinical laboratories worldwide as this 
technology provides highly robust, dependable and 
reproducible results. Various detectors like fluo-
rescence, UV, PDA, electrochemical and MS are 
used with UPLC of which UPLC/MS or 
UPLC/MS/MS has been adopted successfully in 
clinical laboratories [25, 26]. 
SAMPLING TECHNIQUES IN TDM 
 Routinely, ATV concentrations are measured in 
blood plasma obtained by venepuncture tech-
niques. However, venous sampling is difficult for 
repeated sampling and in some populations, such 
as neonates, there are always logistical challenges 
when nonhospital-based sampling is required. A 
proper bio-analytical method is crucial for the 
measurements of drug level in matrices suitable 
for the patient. Special attention must be paid to 
bio-analytical methods in these patient-friendly 
matrices. Patient-friendly drug monitoring of 
antiretroviral drugs includes dried blood spots 
(DBS), hair, and saliva. The discussion of the 
sampling technique is out of the scope of this re-
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view and hence we recommend the readers to refer 
to the article “Bio-analytical issues in patient-
friendly sampling methods for therapeutic drug 
monitoring: focus on antiretroviral drugs” [24]. 
ANALYTICAL METHODS FOR TDM OF 
ARV 
 At present, there are five major classes of ARV 
drugs viz. nucleoside reverse transcriptase inhibi-
tor [NRTI], nonnucleoside reverse transcriptase 
inhibitor [NNRTI], Protease inhibitors [PI], fusion 
inhibitor and integrase inhibitor [IIs]. 
Nucleosidereverse Transcriptase Inhibitors 
(NRTIs) 
 The first generation of ARV drugs is NRTIs 
permitted to treat HIV [25]. Reverse transcriptase 
is an HIV enzyme that converts viral RNA into 
DNA in host CD4 cells and the process is known 
as reverse transcription. NRTIs inhibit the enzyme 
reverse transcriptase and prevent the synthesis of 
DNA. Without reverse transcriptase, HIV cannot 
replicate and infection cannot spread. Nucleoside 
analogues possess structural similarity with the 
natural building blocks of DNA and have to un-
dergo phosphorylation to become active in the 
body. NRTIs are falsely chosen by reverse tran-
scriptase to build the faulty DNA that denies fur-
ther addition of natural nucleotides. Thus, the new 
DNA built incorrectly led to halt HIV replication 
[27]. Following are some NRTIs used for HIV 
therapy: Zidovudine [ZDV/AZT], Didanosine 
[DDI], Stavudine [d4T], Lamivudine [3TC], 
Abacavir[ABC], Emtricitabine [FTC], Tenofovir 
disoproxil fumarate [TDF], Adefovir [ADV]. 
Zidovudine [AZT] 
 AZT is a thymidine analogue NRTI approved 
in March 1987. Chemically, it is an 1-[[2R,4S,5S]-
4-azido-5-[hydroxymethyl]oxolan-2-yl]-5-methyl- 
pyrimidine-2,4-dione, the solubility of which in 
water is 20100 mg/L [at 25 °C] with a logP value 
of 0.05. It was the first FDA approved ARV for 
the treatment of HIV. 
 Various methods have been developed for the 
quantitative determination of AZT including 
chromatography, fluorescence polarisation immu-
noassay, using diamond paste based immune sen-
sor, fluorescence spectroscopy and voltammetry 
[26-38]. Castro and co-workers described a new 
selective and sensitive adsorptive stripping volt-
ammetry method for AZT determination at the 
submicromolar concentration levels [39]. This 
technique was based on the controlled adsorptive 
accumulation of AZT at the mercury film elec-
trode, followed by a linear-sweep adsorptive strip-
ping voltammetry analyses. However, the first 
quantitative determination of AZT on HPLC is 
credited to Klecker et al. who, during the clinical 
pharmacokinetic studies quantified AZT levels in 
plasma, cerebrospinal fluid and urine by isocratic 
evaluation on C18 reverse-phase column [40]. 
Later, AZT became a pillar in the drugs combina-
tion called HAART, which contains a minimum of 
two NRTIs and one NNRTI in a fixed dose com-
bination. Combination of the different classes of 
ARV drugs is used together to prolong the survival 
of HIV patients. Due to the increased prevalence 
of drug-drug interaction in and with HAART re-
gime, several assay methods for multi and single -
component quantitative analysis are developed. 
Jung et al. in 2007 developed LCMS assay for si-
multaneous estimation of 17 ARV drugs in human 
plasma for quantitative analysis while Nandi et al. 
in 2013 reported an assay for simultaneous quanti-
fication of AZT, 3TC, and NVP in human plasma 
with HPLC-UV method [41,42]. Similarly, simul-
taneous quantitation of 3TC, AZT and NVP in 
human plasma by LC-MS/MS assay was reported 
by Krishna et al. [43]. 
 Inside the cell, AZT undergoes phosphorylation 
reaction to give active AZT triphosphate metabo-
lite. This active metabolite blocks the DNA syn-
thesis by inhibiting the reverse transcriptase en-
zyme and chain termination process [44]. Hence, 
several methods have been developed to determine 
AZT concentration inside the cells which are de-
scribed in Table 1 of this review. 
Lamivudine [3TC] 
 Lamivudine [2'-deoxy-3'-thiacytidine, 3TC], 
approved in 1997, is a cytidine analogue NRTI 
NH
ON
O
H3C
O
NN+
~N
OH  
Zidovudine 
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Table 1. Multicomponent methods to assay the concentration of ARV drugs. 
Year/ 
Ref 
Analytes  
[Extraction 
Method] 
Separation- 
Detector 
Column 
M
at
ri
x 
R
un
 ti
m
e 
[m
in
] 
Elution Advantage 
1998 / 
[264] 
APV, IDV, 
NFV, RTV and 
SQV. 
[SPE] 
HPLC-UV 
[210 and 239 
nm ] 
ZorbaxÒ SB-C 
column [75 x 4.6 
mm I.D. /particle 
size 3.5 µm; pro-
tected by a Chrom-
guard column 
[1033 mm I.D.] 
P 20 
Isocratic , flow rate: 1.5 ml/min, 
Mobile Phase: CH3CN plus dis-
tilled water containing 25 mM 
sodium acetate and 25 mM hex-
ane-1-sulfonic acid and adjusted 
to pH 6.0 with hydrochloric acid 
37% [40.5: 59.5, v/v]. 
This assay meets all current 
requirements of the valida-
tion of a bio-analytical 
methodology and covers the 
concentration ranges of 
interest for use in pharma-
cokinetic 
Studies. 
2000/ 
[150] 
APV, EFV, 
IDV, NFV, 
RTV, SQV, 
ABC, Dida-
nosin, 3TC, 
NVP, D4T and 
AZT. [SPE] 
HPLC-UV 
[260 nm] 
Symmetry Shield 5 
µm C18 column 
[250 x 4.6 mm 
I.D.] [Waters] 
protected by a 2 
µm Upchurch filter 
P 30 
Gradient, flow-rate : 1.3 ml/min, 
Mobile phase is composed of 
0.04 M NaHPO buffer with 4% 
[v/v] OSA and CH3CN [50: 50, 
v/v]. 
This is a sensitive, specific 
and validated assay for the 
simultaneous quantitative 
determination of 12 ARV 
drugs from different thera-
peutic classes. 
2000/ 
[151] 
IDV, 
APV, SQV, 
RTV, NFV 
EFV. [SPE] 
HPLC-UV 
[201 nm] 
ChromCart car-
tridge column [125 
x 4 mm I.D.] filled 
with Nucleosil 100, 
5 µm C18 equipped 
with a guard col-
umn [8 x 4 mm 
I.D.] filled with the 
same packing 
material. 
P 47 
Gradient, flow rate: 1 ml /min, 
Mobile phase A: pure CH3CN. 
Mobile phase B: 11.8 ml 8.5% 
H3PO and 0.2 g sodium 
heptanesulfonate to 988. Mobile 
phase C: 0.3% AcOH in CH3CN. 
This optimised HPLC 
method provides a fairly 
simple procedure for simul-
taneously determining five 
currently used PIs and EFV 
in plasma of HIV-infected 
patients. 
2001/ 
[221] 
APV, IDV, 
NFV, RTV, 
SQV and NVP. 
[liquid–liquid 
extraction] 
HPLC-UV 
[239 to 320] 
Symmetry 5 µm 
C18 column [250 x 
4.6 mm I.D.] pro-
tected with a Sym-
metry 5 µMC 
18precolumn [20 x 
3.9 mm I.D.]. 
P 35 
Gradient, flow rate: 0.9 ml/min 
Mobile phase A: CH3CN and 
0.025 M tetramethylammonium 
perchlorate in 0.2% aqueous 
trifluoroacetic acid [55: 45 [v/v]], 
Mobile phase B: CH3OHand 
0.025 M tetramethylammonium 
perchlorate in 0.2% aqueous 
trifluoroacetic acid [55: 45 [v/v]]. 
This method allows simul-
taneous estimation of PIs 
and NVP for TDM in blood 
plasma.  
2001/ 
[122] 
I.S, IDV, 
AMP, RTV, 
SQV, NFV, 
EFV, NVP and 
DLV. 
[liquid– 
liquid  
extraction] 
HPLC-MS 
[SIM] 
Supelcosil LC-18-
DB, 7.5 cm × 4.6 
mm, 3µm  
analytical 
P 10 
Gradient, flow rate: 0.8 mL/min, 
Mobile phase A: H2O, Mobile 
phase B: CH3CN. 
The very short analysis time 
[10 minutes], liquid–liquid 
extraction, simple mobile 
phase without buffer and 
small sample size are the 
key advantages of this 
method. 
2001/ 
[61] 
Zalcitabine, 
3TC, d4T, dida-
nosine, AZT and 
ziagen , IDV, 
NFV, SQV, 
RTV NVP, 
Delavirdin and 
EFV. 
[SPE] 
HPLC-UV 
[250] 
Luna C18 columns 
150 x 4.6 mm.  
P 55 
Gradient, flow rate: 0.85 ml/min 
Method A: Mobile Phase A: 
HPLC grade CH3CN, Mobile 
Phase B: HPLC grade H2O 
Method B: The gradient was 
formed between 0.004 M sulfuric 
acid and CH3CN [8 to 63% 
CH3CN in 45 min with a 5-min 
hold at 63%]. 
Two rapid and simple SPE–
HPLC methods presented in 
this paper covering analysis 
of 13 drugs. 
(Table 1) contd…. 
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Year/ 
Ref 
Analytes  
[Extraction 
Method] 
Separation- 
Detector 
Column 
M
at
ri
x 
R
un
 ti
m
e 
[m
in
] 
Elution Advantage 
2003/ 
[225] 
IDV, APV, 
RTV, LPV, 
SQV, 
NFV and NFV 
metabolite M8. 
[liquid– 
liquid extrac-
tion] 
HPLC-
UV[210 and 
239nm] 
Nova-Pak C18 col-
umn, 3.93150 mm.  
P 30 
Gradient, Flow rate : 1 ml /min, 
Mobile Phase A: 140 ml of 
CH3CN, 75 ml triethylamine, 
Mobile phase B: 160 ml of 5 mM 
sodium dihydrogen phosphate, 
pH 6. 
This assay was quality 
controlled by an interna-
tional interlaboratory qual-
ity control program for the 
TDM in HIV infection. 
More than 13 laboratories 
from Europe, Canada, USA 
and Australia participated in 
this programme. 
2003/ 
[62] 
Zalcitabine, 
3TC, Dida-
nosine,D4T, 
AZT, ABC and 
NVP. 
[SPE] 
UV, 269 nm 
[0–11 min], 
250 nm [11– 
14 min], 271 
nm [14–24 
min] [24–33 
min]. 
Polarity dC [150 x 
33.9 mm, 5.0-µm 
particle size, Waters] 
with a guard column of 
Polarity dC [20 x 33.9 
mm, 5.0-µm particle 
size, Waters]. 
P 33 
Gradient, flow-rate : 1.1 ml/min, 
Mobile Phase A: 10 mM ammo-
nium acetate buffer [pH 6.5], 
Mobile Phase B: 200 ml of mo-
bile phase A [pH 6.5] mixed with 
500 ml of CH3CN and 300 ml of 
CH3OH. 
This method is useful for 
simultaneous determination 
of six NRTIs and NVP.  
2003/ 
[166] 
IDV, APV, 
EFV, SQV, 
NFV, NVP, 
RTV and LPV. 
[liquid– 
liquid extrac-
tion] 
LC-MS Nucleosil C18 HD, 5-
mm particle size col-
umn [12.5 cm x 2mm] 
, protected with a 
guard column [8 x 2 
mm]. 
P 
21 
 
Gradient, flow Rate: 200 ml 
/min. Mobile Phase A: CH3CN 
containing 30% methanol and 
ammonium carbonate buffer pH 
9.3 [5: 95, v/v], Mobile Phase B: 
CH3CN containing 30% CH3OH 
and ammonium carbonate buffer, 
pH 9.3 [95: 5, v/v]. 
The method is simple, fast, 
accurate and suitable for PIs 
[APV, IDV, LPV, NFV, 
RTV, SQV] and NNRTIs 
[EFV, NFV]. 
2004/ 
[158] 
NVP, IDV, M8 
APV, NFV, 
SQV, RTV, 
EFV 
ATV and LPV. 
[liquid– 
liquid extrac-
tion] 
HPLC-UV 
[320 nm 
before 8 min 
and 259 nm 
after 8 min] 
WATERS Symmetry® 
5µm C18 column 
[250×4.6mm i.d.] 
protected with a 
WATERS Symmetry® 
5µM C18 pre-column 
[20×3.9mm i.d.] 
P 35 
Gradient, flow rate: 0.9 ml/min, 
Mobile Phase A: CH3CN and 
0.025M tetramethylammonium 
perchlorate in 0.2% aqueous 
trifluoroacetic acid [55: 45 [v/v]], 
Mobile phase B: CH3OH and 
0.025M tetramethylammonium 
perchlorate in 0.2% aqueous 
trifluoroacetic acid [55: 45 [v/v]]. 
This method is based on a 
HPLC assay coupled with 
UV detection that allows 
the monitoring of PI and 
NNTRI 
with limits of quantitation 
which are consistent with 
therapeutic through plasma 
concentrations of PI 
and NNRTI.  
2005/ 
[110] 
3TC,  
didanosine, 
d4T, AZT  
and ABC 
[SPE ] 
UV [260 nm] Symmetry Shield RP 
C18 column 
[150mm × 4.6mm 
i.d./particle size 3.5 
µm] protected by a 
Symmetry Shield 
RP18 guard column 
[20mm×3.9mm i.d./ 
particle size 3.5µm].  
P 24 
Gradient, flow rate 1.0 ml/min, 
Mobile phase A: acetate buffer: 
CH3CN [95: 5, v/v]. Mobile 
phase B: acetate buffer: CH3CN 
[76: 24, v/v]. 
This approach requires less 
plasma sample with assay 
accuracies of about 92–
102%.  
2005/ 
[367] 
NVP, IDV, 
M8, 
SQV, NFV, 
APV, ATV, 
RTV, LPV and 
EFV. [liquid– 
liquid  
extraction] 
HPLC-UV 
[210 nm] 
Symmetry Shield  
3.5 µm RP18 column 
[15 cm 34.6 mm 
ID] equipped with a  
2-cm pre-column 
packed with the same 
material [Waters].  
P 60 
Gradient, flow rate: 1 mL/min, 
Mobile phase A: 15 mM phos-
phate buffer, pH 4.2, Mobile 
phase B: CH3CN. 
The required plasma sample 
is 500 µL. This procedure 
allows the simultaneous 
determination of the differ-
ent PIs plus M8, and the 
NNRTIs with good preci-
sion and accuracy in the 
range 50 to 10,000 ng/mL. 
Because all compounds are 
monitored at 
a single wavelength [210 
nm], this HPLC method 
does not require the use of 
an expensive photodiode 
array detector. 
(Table 1) contd…. 
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Year/ 
Ref 
Analytes  
[Extraction 
Method] 
Separation- 
Detector 
Column 
M
at
ri
x 
R
un
 ti
m
e 
[m
in
] 
Elution Advantage 
2005/ 
[142] 
APV, NFV, IDV, 
LPV, SQV, RTV, 
ATV, NVP and 
EFV. 
[Protein precipita-
tion ] 
LC-MS/MS 
[MRM] 
Phenomenex 1 
Synergy Max RP 
LC column [150 x 
2 mm, 4m].  BS 8 
Gradient, Flow rate : 0.5 
mL/min, Mobile phase A: 
[97: 3 
CH3OH/H2O [v/v], 0.1% 
acetic acid, 10mM NH4Oac], 
Mobile Phase B: [10:90 
MeOH/H2O [v/v]]. 
This method described a 
robust LC-MS/MS method 
for multi component analy-
sis of PI and NNRTI drugs 
in patient plasma and for 
the first time in DBS. 
2006/ 
[63] 
3TC, Zalcitabine, 
FTC, 
Didanosine,D4T, 
ABC, 
AZT, NVP, IDV, 
SQV, APV, NFV, 
RTV, LPV, EFV 
and ATV. 
[SPE] 
UV [240 and 
260 nm] 
C18 Symmetry 
column 
[250mm×4.6mmI.
D.] Particle size of 
5.0µm [Waters] 
with a Waters 
guard column 
[20×3.9mm I.D.].  
P 35 
Gradient, flow rate: 1.0 
mL/min, Mobile phase A: 
0.01M 
KH2PO4], Mobile Phase B: 
[CH3CN]. 
This method id useful in 
simultaneous determination 
of the large number of anti-
HIV drugs. 
2007/ 
[41] 
EFV, NVP, 
ZDV, d4T,  
ABC, 3TC, 
DDC, DDI, IDV, 
NFV, RTV, ATZ, 
TNF, SQV,LPV, 
APV and De-
lavirdine . [liquid– 
liquid extraction] 
HPLC-
MS/MS 
Aquasil® C18, 50 
x 2.1 mm column, 
with a 
particle size of 5 
µm.  P 18 
Gradient, flow rate: 0.5 mL/ 
Min, Mobile phase A: 
0.05% formic acid in H2O 
[v/v], Mobile phase B: 
CH3OH[v/v] with 0.05% 
formic acid. 
This is the first LC-MS/MS 
method that simultaneously 
quantifies 17 ARV agents in 
small volumes [50 µL] of 
plasma. 
 
2007/ 
[179] 
IDV, 
NVP, M-8, IS, 
NFV, SQV, ATV, 
APV, DRV, RTV, 
LPV, EFV and 
TPV. 
[liquid– 
liquid extraction] 
MS Atlantis dC-18 3µ 
column 
[150mm×2.1mm 
i.d.] Guarded with 
C18 
[4.0mm×3.0mm 
i.d.] pre-column.  
P 20 
Gradient, flow rate: 100 l/h. 
Mobile phase A: HPLC 
grade water with 0.05% 
formic acid, Mobile Phase B: 
HPLC grade CH3CN with 
0.05% formic acid]. 
Small volumes [50µl] of 
plasma are required for 
assessment. High extraction 
efficiency and low limit of 
quantification are the addi-
tional characteristics. 
2007/ 
[200] 
APV, IDV, 
ATV, RTV, LPV, 
SQV, NFV 
and M8-NFV 
metabolite. [SPE] 
HPLC-UV 
[215 nm] 
fluorescence 
detector [280 
and 340 nm] 
Allsphere hexyl 
5µ column 
[150mm×4.6mm 
i.d.].  
P 60 
Isocratic, flow rate : 1 
ml/min, The mobile phase 
was a mixture of CH3CN, 
methanol and 15mM sodium 
dihydrogen phosphate buffer 
pH 
4.5 [35/20/45, v/v/v]. 
Few of the advantages of 
this method includes 1) 
isocratic separation of all 
presently available PIs; 2) 
specific and fast determina-
tion of all compounds with 
UV 
and/or fluorescence detec-
tion; 3) no interferences 
with co-medications or 
metabolites.  
2007/ 
[163] 
NVP, IDV, APV, 
SQV, ATV, RTV, 
LPV, EFV and 
NFV. [liquid–
liquid extraction] 
HPLC-UV 
[212nm] 
S-3, 
3.0mm×150mmY
MC-Pack Octyl C8 
column [Waters] 
protected by the 
addition of a  
0.5 µm filter  
apparatus. 
P 18 
Isocratic, flow rate: 0.4 
ml/min The mobile phase 
consisted of 52% 25 mM 
monobasic potassium 
phosphate [pH 4.90], 48% 
CH3CN, vol: vol. 
This assay is entirely 
isocratic involving only two 
stable solvent components. 
This method is short and 
requires only 200µl of 
plasma for the analysis.  
(Table 1) contd…. 
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2007/ 
[66] 
Triphosphate 
metabolites of 
AZT, 3TC and 
ABC 
[SPE] 
MS/MS 
[SRM] 
Aquasil C18 col-
umn 
[2.1mm×50mm, 
3µm particle size] 
with a 
 Uniguard Aqusil 
C18 
guard column 
[2.1mm×10mm,3µ
m particle size].  
PBMC 3 
Gradient, flow rate: 
200µl/min, Mobile phase 
A: H20 with 0.1% acetic 
acid, Mobile phase B: 
CH3OH with 0.1% acetic 
acid. 
This assay method has the ad-
vantage of allowing the meas-
urement of ZDV-TP, 3TC-TP 
and CBV-TP either together or 
individually in samples ex-
tracted from PBMC.  
2008/ 
[112] 
D4T, 
3TC, DDI, FTC, 
AZT, ABC and 
TDF. 
[SPE] 
MS/MS 
[SRM] 
Atlantis® T3 
column 
[100mm×2.1mm, 
3-µm particle 
diameter, Waters]. 
P 14 
Gradient, flow rate: 
250µL/min, Mobile 
Phase A: Water with 
0.05% formic acid, 
Mobile Phase B: CH3OH 
with 0.05% formic acid. 
This method is simple and short, 
applicable for determining 7 
N[t]RTIs, requires small plasma 
sample volume which suits well 
for the quantification of zido-
vudine in premature infants and 
neonates.  
2008/ 
[85] 
TDF and FTC. 
[SPE] 
 
LC-MS/MS 
[multiple 
reaction-
monitoring] 
Chromolith Speed 
Rod RP18 column 
[50mm×4.6mm]. 
P 2 
Isocratic, Flow rate: 0.7 
ml/min. Mobile phase 
consist of CH3CN and 
ammonium acetate [pH 
3.0, 40mM]  
[20: 80, v/v]. 
This method provides excellent 
specificity and linearity with a 
limit of 
quantification range between 10 
ng/ml to 25 ng/ml.  
2008/ 
[203] 
NVP, 
IDV, M8, 
RGV, SQV, NFV, 
APV, DRV, ATV, 
RTV, EFV, LPV, 
ETV and TPV. 
[SPE] 
HPLC-PDA 
[210–320 nm] 
Luna 
5m C18 column 
[150 x 4.6 mm], 
protected with a 
C18 guard column 
[4.0 x 3.0 mm ]. 
P 28 
Gradient, flow rate: 1 
mL/min; Mobile phase 
A: KH2PO4 50 mM with 
orthophosphoric acid, 
pH: 3.23 . Mobile phase 
B: CH3CN. 
 
This assay relies on SPE cou-
pled with a new high-sensitive 
Waters 2998 PDA detector, 
which is simple, reliable, sensi-
tive, and not expensive. Multiple 
channel acquisition in the range 
of 210–320 nm with a PDA 
detector which allows peaks 
purity, ensuring the absence of 
interferences. 
2009/ 
[368] 
AZT and NVP. 
[liquid– 
liquid extraction] 
UV-PDA 
[246 nm] 
Phenomenex 
LUNA C18, col-
umn [250×4.6 mm 
i.d., 5µm].  
P 10.2 
Isocratic, flow rate of 0.9 
mL/min Mobile phase A: 
H2O, pH 3.0, adjusted 
with orthophosphoric 
acid], Mobile Phase B: 
CH3CN [73: 27, v/v]. 
This method requires small 
plasma sample. It is based on the 
rapid protein precipitation ex-
traction. 
2009/ 
[178] 
DRV, RTV and 
ETR. 
[Liquid – Liquid 
extraction ] 
LC–MS 
[Single ion 
monitering ] 
Agilent Zorbax® 
XDB C8 
[50mm×3.0mm, 
1.8µm] column 
with an Agilent 
RRLC in-line 
filter. 
P 8 
Gradient, flow rate: 0.65 
to 0.75 mL/min. Mobile 
phase A: Water with 
0.01% formic, Mobile 
phase B: CH3CN with 
0.01% formic acid. 
This method was optimized 
using a sub-2µm column, and is 
quick, accurate, sensitive, spe-
cific, and highly reproducible. It 
demonstrates good linearity, 
precision and accuracy within a 
wide concentration range 
[0.002–2.0µg/mL].  
2009/ 
[169] 
RAL, ETR, 
APV, ATV, DRV, 
EFV, IDV, LPV, 
RTV, SQV and 
TPV. 
[liquid–liquid 
extraction] 
LC-MS/MS 
[MRM] 
Sunfire C18 
100mm x 32.1 
mm, 3.5 mm 
HPLC column.  P 
8 
 
Gradient, flow rate: 0.3 
mL/min, Mobile phase 
A: H2O + ammonium 
acetate 2 mM with for-
mic acid 0.1%, Mobile 
phase B: CH3OH with 
formic acid 0.1%.  
This method requires a small 
volume of plasma for analysis 
[100 mL].  
(Table 1) contd…. 
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2009/ 
[176] 
RAL, MVC, 
DRV, and ETR. 
[SPE] 
LC-MS/MS 
[SRM] 
Waters Atlantis, 
2.1mm×50mm, 
dC18 3µm.  
P 10 
Gradient , flow-rate : 0.3 
ml/min, Mobile Phase A: 
2mM ammonium acetate 
in ultrapure 
water containing 0.1% 
formic acid of pH 2.8, 
Mobile Phase B: MeCN 
0.1% formic acid. 
This method enables the simul-
taneous assessment of RAL–
glucuronide. This method is 
suitable for the TDM service of 
new regimen combinations 
administered as salvage therapy 
to patients having experienced 
treatment failure, and for whom 
exposure, tolerance and adher-
ence assessments 
are critical.  
2010/ 
[141] 
NVP, SQV, ATV, 
APV, DRV, RTV, 
LPV, EFV and 
ETV. [liquid– 
liquid extraction] 
LC-MS 
selected ion 
recording 
[SIR] 
 
Atlantis T3 C18 
3µm column 
[150mm×2.1mm 
i.d], protected by a 
Security Guard 
with C18 
[4.0mm×3.0mmi.d.
] pre-column. 
PS 19 
Gradient, flow rate: 0.3 
ml/min, Mobile phase A: 
HPLC grade water with 
0.05% formic acid, 
Mobile phase B: HPLC 
grade CH3CN with 
0.05% formic acid.  
This method utilized glass filter 
papers, which can be safely sent 
by-mail, promoting the practice 
of TDM. 
2010/ 
[177] 
MVC, SQV, RPV, 
NVP, APV, DRV, 
ATV, 
RTV, LPV and 
ETR. [liquid– 
liquid extraction] 
HPLC–
MS/MS 
[SRM] 
Ascentis C18 col-
umn [3µm: 
100mm×2.1mm] 
with a 
2µm guard column, 
C18 Quest column 
saver. 
P 5 
Gradient, flow rate: 
400µl/min, Mobile phase 
A: CH3CN, Mobile 
phase B: H2O with 
0.05% formic acid. 
This assay offers high sensitivity 
for all compounds [LLQ = 5–16 
ng/ml] over a dynamic concen-
tration range, and therefore has 
potential application for numer-
ous pharmacokinetic analyses. It 
requires a relatively small vol-
ume of plasma for analysis 
[100µl]. 
2011/ 
[79] 
IDV, NVP M-8, 
NFV RGV, SQV 
APV, DRV ATV, 
RTV EFV, LPV 
ETV and TPV. 
[liquid– 
liquid extraction] 
LC-MS 
[SIR] 
Atlantis T3 C18 3 
µ column 
[150mm×2.1mm 
I.D.] Guarded with 
C18 
[4.0mm×3.0mm 
I.D.] pre-column.  
PBMC 28 
Gradient, flow rate: 0.3 
mL/min. Mobile phase 
A: mixture of water 
[0.05% formic acid], 
Mobile phase B: CH3CN 
[0.05% formic acid]. 
Useful for routine determination 
of PIs, NNRTIs and RGV in 
PBMC. Low blood volume, 
good extraction efficiency and a 
low limit of quantification make 
this method suitable for use in 
clinical trials.  
2012/ 
[43] 
3TC, AZT and 
NVP. [SPE] 
MS/MS 
[MRM] 
Hypurityad-
vanceC18 col-
umn[50mm x 4.6 
mm,5 mm] 
P 3.5 
Isocratic, flow rate: 0.8 
mL/min. Mobile phase 
consisting of CH3CN 
with 0.1% formic acid 
[74: 26, v/v]. 
Simple sample preparation with 
adequate sensitivity and short 
run time are the advantage of 
this assay method.  
2012/ 
[211] 
3TC, LPV, RTV 
and AZT. 
[SPE] 
MS/MS 
[MRM] 
Vydac column 
[250 3 1 mm i.d.] 
packed with 3.0-
µlm C18 particles. 
P 16 
Gradient , flow rate: 70 
µL/min, Mobile phase 
A: CH3CN, Mobile 
phase B: ultrapure water 
, both solvents contained 
0.2% [v/v] formic acid. 
Use of quadrupole-quadrupole-
time-of-flight mass analyser 
offers advantages of obtaining 
very high specificity towards the 
selected analytes.  
2013/ 
[42] 
AZT, 3TC and 
NVP. [liquid– 
liquid extraction] 
UV [270nm ] Hypersil BDS, C18 
column. 
P 10 
Isocratic , flow rate: 0.85 
ml/min, Mobile phase : 
mixture of buffer [0.1M 
ammonium 
acetate in 0.5% acetic 
acid, v/v] and methanol 
[40: 60, v/v]. 
Simple mobile phase composi-
tion, short run time, and liquid-
liquid extraction are the key 
advantage of this assay method. 
(Table 1) contd…. 
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2013/ 
[89] 
AZT, ABC, FTC, 
3TC, TDF and 
ribavirin. [liquid– 
liquid extraction] 
LC-MS/MS 
[multiple 
reaction-
monitoring 
Synergy Polar 
reversed phase C18 
column [150 mm × 
2.0 mm ID, 4 µm 
particle size, pro-
tected with an 
inline filter.  
P 11 
Gradient, Flow rate: 300 
µL/min , Mobile phase 
A: 0.1% [v/v] formic 
acid in water, Mobile 
phase B: 0.1% [v/v] 
formic acid in methanol. 
This was the first method de-
scribing the simultaneous quan-
tification of the anti-HCV drug 
ribavirin together with the anti-
HIV drugs AZT, ABC, FTC, 
3TC and TDF. The method is 
simple, sensitive, specific and 
reproducible and can be used in 
clinical practice to monitor 
N[t]RTI plasma concentrations 
in selected cases to optimize 
therapy. 
2013/ 
[215] 
APV, ATV, Boce-
previr, DRV, 
EFV, 
EVG, ETR, IDV, 
LPV, MVC, NVP, 
RAL, RTV, SQV, 
TDF and TPV. 
[liquid– 
liquid extraction] 
UPLC-
MS/MS 
[MRM] 
Waters Ac-
quityHSST3 
1.8µM 
[2.1×50mm] UPLC 
column[Waters 
Corp., Milford, 
MA, USA]. 
P 4.2 
Gradient, flow rate of 
0.6ml/min, Mobile phase 
A: H2O with formic acid 
0.1% [V/V], Mobile 
phase B CH3CN with 
formic acid 0.1% [V/V]. 
Useful for simultaneous quanti-
fication of EVG, RAL, MVC, 
ETR, TDF as well as 10 other 
ARV agents. This assay required 
small volumes of plasma. 
2014/ 
[147] 
ATV, 
ATV-IS, 
DRV, 
EFV, 
EFV-IS, 
LPV, 
RTV and 
RTV-IS. [SPE] 
UPLC-
MS/MS 
[MRM] 
ACE C18 column 
[3 x 100 mm]. 
PBMC 5 
Gradient, flow rate: 500 
µl/min, Mobile phase 
consisted of CH3CN: 
water: formic acid [60: 
40: 0.1]. 
The novelty of this assay lies in 
the sensitivity attained with the 
small sample volume. This is an 
important assay to study intra-
cellular pharmacology of ARV 
drugs.  
2014/ 
[369] 
APV, ATV, DRV, 
IDV, LPV, NFV, 
RTV, SQV, TPV, 
FTC, 
3TC, 
TFV, 
AZT, 
EFV and NVP. 
[liquid–liquid 
extraction 
LC-MS 
[SRM] 
Thermo Scientific 
Hypersil Gold 
PFP, 100× 3mm 
column. 
P 16 
Gradient, flow rate: 500 
µl/min, Mobile phase A: 
H2O with 0.1% acetic 
acid, Mobile phase B: 
CH3CN with 0.1% acetic 
acid. 
This method is validated, for the 
qualitative monitoring of 15 
ARV agents in human plasma. 
The method requires minimal 
sample pre-treatment, and based 
on the high mass accuracy of the 
Exactive-MS.  
2014/ 
[216] 
IDV,SQV, NFV, 
APV, DRV, ATV, 
RTV and LPV. 
[liquid–solid 
extraction] 
Parallel 
UPLC-
MS/MS 
[MRM] 
Kinetex XB-C18 
column [100 × 2.1 
mm I.D., 1.7 µ m, 
with Krud Katcher 
Ultra filter, Pheno-
menex, Torrance, 
CA, USA]. 
PS 4 
Gradient, flow rate: 0.6 
ml/min to 0.4 ml/min, 
Mobile phase A: 0.1% 
acetic acid in water, 
Mobile phase B: 0.1% 
acetic acid in CH3CN. 
Inherent advantages of this DBS 
based assay is the simplify sam-
ple collection. This method uses 
a parallel UHPLC–MS/MS 
platform which was developed 
and validated for the analysis of 
eight PIs in dried spots of 
plasma on filter paper. One 
sample can be injected every 4 
min by alternating columns, 
however the assay can also run 
on a single column without the 
need of revalidation but at the 
expense of 50% increased 
analysis time.  
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2014/ 
[189] 
DTG 
and RPV. 
[SPE] 
LC-MS/MS 
[MRM] 
Phenomenex 
Luna 5 µm 
Phenyl-Hexyl, 2 
mm × 
50 mm. 
P 2.5 
Gradient, Mobile Phase A : 
100% H2O, 10 mM ammo-
nium acetate, 
0.1% acetic acid, Mobile 
Phase B: 100% CH3CN. 
 
This method allows accurate and 
precise determination of 
plasma concentrations of two 
recently licensed ARV 
agents including the novel INSTI 
DTG. The limits of quantification 
are consistent with trough plasma 
concentrations of 
ARV agents whereas use of deu-
terated-internal 
standard prevents matrix effect. 
2016/[19
1] 
ATV, DTG, EFV, 
ETV, LPV, RGV 
DRV RPV and 
TPV. [SPE] 
HPLC-UV XBridge C18 
[4.6 mm×150 
mm, 
3.5 µm; Waters] 
column.  
P 25 
Gradient: Flow rate: 1 
mL/min, Mobile phase A: 
Acetonitrile 50 mM, Mo-
bile phase B; Acetate 
buffer at pH 4.5.  
Good extraction efficiency and low 
limit of quantification 
makes this method suitable for use 
in clinical trials and for TDM.  
Note: P: Plasma, DBS: Dried Blood spot, DPS: Dried Plasma Spot, PBMC: Peripheral blood Mononuclear Cell, SPE: Solid Phase Extraction. 
 
effective against both HIV [type I and II] and 
hepatitis B virus [43, 44]. Chemically, it is an 4-
amino-1-[[2R,5S]-2-[hydroxymethyl]-1,3-oxathiolan-
5-yl]pyrimidin-2-one, the solubility of which in 
water is 70 mg/ml with a logP value of -1.4. 
O
S
OH
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Lamivudine 
 It is a prodrug and metabolized intra-cellularly 
to its active 3TC triphosphate metabolite by cellu-
lar kinases enzymes [45]. Because of the poly-
pharmacy dosage regimen, several drug-drug in-
teractions of 3TC are noted in the literature [46]. 
Monitoring NRTI base therapy could be very vital 
for drug-drug interaction studies. Hence, several 
quantitative assay methods are reported in the 
literature for 3TC. Harker et al. reported the first 
validated assay for the quantification of 3TC in 
human serum and urine [47]. This method was de-
veloped for monitoring clinical investigations and 
getting pharmacokinetic information. Hsyu et al. 
proposed another assay for quantitative determina-
tion of 3TC on HPLC [48]. A radioimmunoassay 
for the quantitation of 3TC in ng/mL concentra-
tions was developed and validated to determine 
intracellular phosphorylated 3TC [49]. However, 
the specified radio-ligand and antiserum are not 
economically accessible for this radioimmunoassay. 
 Plumb et al. developed an HPLC assay for the 
sulphoxide metabolite of 3TC in human urine and 
observed that it is the significant metabolite in rat 
and dog urine on oral administration [50]. It was 
then hypothesized that this sulphoxide metabolite 
might also be available in the urine of volunteers 
receiving 3TC orally/IV route. Zhou et al. devel-
oped a rapid assay for the quantitation of 3TC in 
human serum by HPLC with UV detection, which 
was found to be more desirable since it uses only 
100 µl of serum for analysis as compared to 
Plumbs et al. method which needs 1 ml of the 
sample [51]. Hoetelmans et al. reported the assay 
for the determination of 3TC in human plasma, 
saliva, and cerebrospinal fluid in ng/mL concentra-
tion using HPLC with UV detection [52]. 
 Until 1998, all the methods reported for 3TC 
were based on HPLC with UV detection. No 
method on HPLC with tandem mass spectrometry 
for the simultaneous determination of 3TC with 
other anti-viral drugs in human serum was re-
ported. Kenney et al. in 2000, Estrela et al. in 
2004 and Rower et al. in 2012 developed assays 
for simultaneous determination of AZT and 3TC 
in human serum and followed by 3TC and AZT in 
the seminal fluid by Pereira et al. on HPLC with 
tandem mass spectrometry [53-56]. Considering 
the cost of mass detector, Verma et al. and 
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Wattananat et al. separately developed simultane-
ous assay methods for 3TC and AZT on HPLC 
with UV detector [57, 58]. Fan et al. reported vali-
dated HPLC assay for simultaneous determination 
of 3TC, d4T and EFV in human serum using gra-
dient elution on HPLC with triple quadrupole mass 
spectrometry detection with ESI [59]. Ionisation 
polarity switch was used in this method as the an-
tiviral combination including drugs from NRTI 
and NNRTI class that possess varying physio-
chemical characteristics like polarity and solubil-
ity. Aymard et al., Simon et al., Thiam et al., Rezk 
et al., Notari et al., Tarinas et al. and Pynnonen et 
al. separately developed simple bio-analytical 
assay methods to quantitatively determine plasma 
concentrations of several ARV drugs including 
3TC in a single blood sample [60-65]. 
 Efficacy of NRTI depends on many variables 
including pharmacokinetics, metabolism, inter-
individual genetic variability in enzymatic and 
transportation processes and intracellular kinase 
base activation of drugs [66]. These complexities 
in the interactions and variability show how diffi-
cult it is to predict the correlation between plasma 
drug and intracellular triphosphate concentrations. 
Since all the NRTIs undergo phosphorylation to 
form active NRTI triphosphate, it is of concern to 
determine the triphosphate levels in the target cells 
mainly inside the peripheral blood mononuclear 
cell [PBMC]. Few assay methods describing the 
quantification of phosphorylated 3TC in human 
PBMC’s were reported separately by Solas et al., 
Becher et al. and Robbinset al. [66-68]. 
 Nirogi et al. for the first time reported a simple, 
sensitive, selective, precise and reproducible triple 
quad MS method for the simultaneous quantifica-
tion of 3TC, d4T and NVP in DBS cards for ro-
dent pharmacokinetic studies [69]. The benefits of 
this technique over the other revealed strategies 
include: [1] Use of less matrix [20 mL] for spot-
ting clearly indicates the volume of the sample re-
quired at a time reduced appreciably; [2] sensitive 
technique with lower limit of quantification [3TC: 
1 ng/mL, d4T: 1 ng/mL, NVP: 10 ng/mL]; [3] 
minimized biohazard threat; [4] less cost of sample 
storage and transport; [5] simple and precise 
evaluation technique in all matrices including 
whole blood, plasma and DBS. 
Tenofovir Disoproxil Fumarate [TDF] 
 TDF is the acyclic nucleotide analogue of 
adenosine monophosphate approved for HIV 
treatment in 2004 [70]. Chemically, it is an [[2R]-
1-[6-aminopurin-9-yl]propan-2-yl]oxymethylphos- 
phonic acid, the solubility of which in water is 
13.4 mg/mL at 25 0C with a logP value of -1.6. 
TDF is phosphorylated twice to the active diphos-
phate form. 
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Tenofovir disoproxil fumarate 
 High fat meal increases the bioavailability of 
TDF and remains unaffected by normal meal [71]. 
As TDF is eliminated through the kidney and is 
not a substrate for CYP45, its dosage regimen 
needs to be modified in renal complications [72-
77]. Gervasoni et al. showed that HIV-infected 
females with diminished body weight are in dan-
ger to be exposed to elevated TDF plasma trough 
concentrations, eventually bringing about a huge 
threat to produce long-term TDF complications 
[72]. All these factors made TDF an ideal candi-
date for TDM. 
 Several simultaneous multi-component assay 
methods for TDF on HPLC coupled with fluores-
cence, UV and mass detection have been described 
in the literature and discussed in Table 1. Dela-
hunty et al. developed and validated a sensitive 
assay for quantifying plasma TDF concentrations 
by using LC/MS/MS [73]. However, before Dela-
hunty et al.., another research group of Sentenac et 
al. developed an assay for the determination of 
TDF in human plasma samples using reverse 
phase HPLC [RP-HPLC] technique and Rolf et al. 
developed LC assay for TDF in plasma using 
derivatisation with chloroacetaldehyde [74, 75]. 
During the same time, Jullien et al. in 2003 pub-
lished a short communication regarding the deter-
mination of TDF in human plasma by HPLC with 
spectrofluorimetric detection [76]. In 2006, King 
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et al. developed LC-MS/MS assay for the deter-
mination of TDF-diphosphate in human PBMC’s 
[77]. Barkil et al. in 2007 developed an assay for 
the determination of TDF in human plasma using 
combined UV and single MS detector for TDM 
[78]. Considering the importance of intracellular 
NRTIs concentrations, King et al. in 2006, 
D’Avolio et al. and Coulier et al. separately de-
veloped methods for the determination of TNF in 
human PBMC’s which are detailed in Table 1 [79, 
80]. 
Emtricitabine [FTC] 
 FTC is a synthetic fluoro derivative of 
thiacytidine with potent antiviral activity approved 
in 2003. Chemically it is an 4-amino-5-fluoro-1-
[[2R,5S]-2-[hydroxymethyl]-1,3-oxathiolan-5-
yl]pyrimidin-2-one, the solubility of which in wa-
ter is 112 mg/mL with logP value of -1.4. FTC is 
phosphorylated to form FTC 5'-triphosphate 
within the cell. 
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Emtricitabine 
 FTC, when combined with TDF, has shown to-
gether greater HIV RNA suppression compared to 
the combination of AZT and 3TC [81, 82]. Co-
administration of FTC/TDF with antiviral drugs 
that eliminate through kidney by means of active 
tubular discharge may enhance plasma TDF or 
FTC concentrations and/or those of simultaneously 
given drugs [83]. Hence, an analytical assay 
method competent to determine FTC and TDF si-
multaneously in blood plasma was required. For 
this combination, in 2005, Rezk et al. developed 
an assay on HPLC after solid phase extraction 
process whereas Gomes et al. reported LC–
MS/MS method for simultaneous determination of 
TDF and FTC in human plasma [82-85]. 
 FTC undergoes phosphorylation to form active 
FTC triphosphates metabolite using cellular kinase 
enzymes. FTC and phosphorylated metabolite give 
varying pharmacokinetic results [86]. Thus, intra-
cellular FTC nucleotide levels are monitored using 
assays developed and validated on HPLC–UV and 
LC–MS detection [87]. In 2010, Jansen et al. de-
veloped an analytical method for the quantification 
of FTC monophosphate, FTC diphosphate and 
FTC triphosphate in combination with TDF, TDF 
monophosphate and TDF diphosphate in human 
PBMC’s [88]. For simultaneous analysis of FTC 
with other ARV drugs, Kromdijk et al. developed 
LC- MS/MS method for simultaneous determina-
tion of FTC with other antiviral agents like AZT, 
ABC, 3TC, TDF and ribavirin in human plasma [89]. 
V. Abacavir [ABC] 
 Abacavir [carbocyclic 2′-deoxyguanosine, 
ABC] approved in 1998, is a guanosine analogue 
NRTI which is used in the therapy of HIV infec-
tions [90]. Chemically, it is an [[1S,4R]-4-[2-
amino-6-[cyclopropylamino]purin-9-yl]cyclopent-
2-en-1-yl]methanol, the solubility of which in wa-
ter is 77 mg/mL with logP value of 1.2. Only 2% 
of ABC is excreted unchanged in urine while the 
remaining 98% is metabolized by the liver [91, 
92]. The half-life of ABC is about 1.5 h [93,94]. 
Carbovir triphosphate [CBV-TP] is an active me-
tabolite of ABC that gives antiviral effect [95]. 
This CBV-TP showed extended half-life elimina-
tion [> 20 h] on once daily dosing. 
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Abacavir 
 ABC is not appreciably metabolized by cyto-
chrome P450 [CYP] enzymes, and hence it does 
not show any major drug interactions with 3TC, 
ZDV, ethanol or methadone [96-99]. To satisfy the 
needs of clinical pharmacokinetic and drug-drug 
interaction studies, various rapid, selective, and 
robust analytical methods were developed for 
ABC concentration determination. Seshachalam et 
al. developed a validated RP-HPLC method for 
the analysis of ABC and related impurities over 
the range of 0.005–0.2 mg/mL [100]. Uslu et al. 
reported anodic voltammetry assay for the deter-
mination of ABC in pharmaceuticals and serum 
samples [101]. Two different assays have pre-
dicted ABC in human plasma using HPLC–UV 
with a sensitivity of 50 ng/mL and 20 ng/mL, re-
spectively [102,103]. Both the techniques em-
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ployed substantial plasma volume [≥ 300 µL] for 
test sample preparation and extended chroma-
tographic run time [≥ 10min]. Clark et al. have 
reported the determination of ABC in maternal 
plasma, amniotic fluid and foetal and placental 
tissues by a polarity-switching LC/MS/MS tech-
nique [104]. The recovery of ABC was found in 
the range of 53-87%, with the limit of detection 
[LOD] being 1 ng/mL and retention time 5.1 min. 
Ravitch et al. reported an HPLC–UV assay for the 
determination of ABC and its metabolites in hu-
man urine and cerebrospinal fluid with a limit of 
quantitation [LOQ] ≥ 61 ng/mL and extended re-
tention time of 35 min [105]. Similarly, ABC and 
its active metabolites from human PBMC’s were 
analysed by Fung et al. using LC/MS/MS tech-
niques [106]. Liquid chromatographic analysis 
method for the simultaneous determination of 
ABC and mycophenolic acid in human plasma and 
ABC and ZDV in rat tissues has also been reported 
[107,108]. Both these methods are least responsive 
and showed extended chromatographic run time of 
20 min. Two different techniques describe the si-
multaneous determination of triphosphate metabo-
lites of ABC,ZDV, 3TC, and TDF diphosphate in 
human PBMC by LC/MS/MS [109]. Other tech-
niques such as LC/MS/MS, HPLC and MALDI-
TOF/TOF describe simultaneous determination of 
ABC with commonly prescribed ARVs in human 
plasma [110-113]. 
 A potentially useful assay method has been il-
lustrated by Jung et al. to determine ABC and 16 
other ARV drugs in human plasma [50 µL] by po-
larity-switching LC/MS/MS [41]. In this method, 
they utilized a combination of liquid–liquid extrac-
tion and protein precipitation to extract all the 
drugs with at least 75% recovery. However, the 
linear dynamic range established in this assay 
method for ABC was very limited [1–500 ng/mL]. 
Hence, Saux et al. have estimated seven NRTIs 
including ABC in human plasma by LC/MS 
method [112]. In this assay, plasma samples were 
precipitated with acetonitrile to get a mean recov-
ery of 87.9% and LOQ as 20 ng/mL for ABC with 
a runtime of 14 min for the separation of all seven 
drugs. The limit of quantitation achieved in this 
assay was 20 ng/mL for ABC, and the separation 
of all seven drugs was possible in a runtime of 14 
min. Notari et al. used standard addition analysis 
to estimate ABC and five more ARVs in the 
plasma by MALDI-TOF/TOF technology reported 
LOQ as 0.01 pmol/µL for all the drugs [113]. 
NON-NUCLEOSIDE REVERSE TRANS- 
CRIPTASE INHIBITOR [NNRTI] 
 NNRTIs restrain the process of viral DNA syn-
thesis by directly binding to the hydrophobic 
pocket of reverse transcriptase enzyme [25]. 
NNRTIs are classified as 1st generation and 2nd 
generation NNRTIs. 1st generation NNRTIs in-
clude Nevirapine [NVP] and Efavirenz [EFV] and 
2nd generation NNRTIs are Etravirine [ETV] and 
Rilpivirine [RPV]. HIV-2 is naturally resistant to 
NNRTIs. 
Nevirapine [NVP] 
 NVP is the first member of NNRTI class which 
was approved in the USA in 1996. It is a benzodi-
azepine analogue. Chemically, it is an 11-
cyclopropyl-4-methyl-5H-dipyrido[2,3-e: 2',3'-f][1,4] 
diazepin-6-one, the solubility of which in water is 
100 mg/l at neutral pH with logP value of 2.5. 
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 NVP is an inducer of the CYP450 enzyme sys-
tem and also an autoinducer of its own metabo-
lism. Administration of this drug for a period of 15 
days results in enhancement of its oral clearance 
by two-folds and decrease in the half-life from 45 
to 30 h [114, 115]. This helps NVP in reducing the 
level of other co-administered ARVs which are 
metabolized via CYP. These possible drug-drug 
interactions make NVP an ideal candidate for 
TDM. 
 Heeswijk et al. first reported the assay method 
to determine NVP in human plasma by ion-pair 
RP-HPLC with UV detection [116]. Pav et al. of 
Boehringer Ingelheim Pharmaceuticals, USA pre-
sented a validated assay method which described 
HPLC-UV technique for the estimation of NVP in 
human plasma, serum, milk and cerebrospinal 
fluid following solid phase extraction [117]. This 
technique was useful in advanced clinical studies 
of NVP for better therapeutic potential. Few other 
methods have been described for NVP determina-
tion by HPLC [118-121]. Single mass detector was 
first used to detect the NVP plasma concentration 
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by Villani et al. who coupled liquid chromatogra-
phy to a single MS [LC/MS] using ion-trap tech-
nology [122]. Laurito et al. developed a precise, 
sensitive and rapid LC-MS/MS technique for es-
timating NVP in human plasma using dibenzepine 
as the internal standard [IS] [123]. Similarly, Chi 
et al. reported another LC-MS/MS assay for the 
estimation of NVP in human plasma which re-
quired only 50 µl of the sample and hence advan-
tageous for use with paediatric samples [124]. 
 Till 2007, no analytical methods were available 
for the simultaneous estimation of NVP and its 
metabolites. Liu et al. in 2007 first developed and 
validated highly specific and sensitive LC-MS/MS 
assay for the quantification of NVP and its two 
oxidized metabolites, 2 hydroxy nevirapine and 
nevirapine 4-carboxylic acid [125]. Vogel et al. in 
2010 came up with the first assay method of NVP 
on GCMS which has an advantage in terms of 
peak overlapping [126]. Kromdijk et al. in 2012 
used DBSs for the estimation of plasma concentra-
tions of NVP and EFV that offer patient-friendly 
and easy sampling alternative [127]. Other than 
the above-mentioned assay methods, several other 
simultaneous assay methods with other ARVs 
were developed and have been described in Table 1. 
Efavirenz [EFV] 
 EFV is a benzoxazin analogue approved by 
FDA in 1998 for the treatment of patients infected 
with HIV [128]. Chemically, it is an [4S]-6-chloro-
4-[2-cyclopropylethynyl]-4-[trifluoromethyl]-1H-
3,1-benzoxazin-2-one, the solubility of which in 
water is 0.093 mg/L at 250C with logP value of 4.6. 
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Efavirenz 
 The dosing of EFV is once-daily due to its long 
half-life. EFV is usually preferred to treat HIV pa-
tients co-infected with tuberculosis [TB]. Both the 
diseases are life-threatening and treatment be-
comes very difficult due to drug-drug interactions 
between EFV and rifampicin [129, 130]. Side ef-
fects of EFV are found to be associated with the 
EFV plasma concentration and hence, several ana-
lytical methods have been developed to estimate 
its plasma concentration. Various side effects are 
associated with high and low plasma levels of 
EFV particularly in HIV-TB co-infected patients 
for which TDM studies become necessary. EFV 
levels are directly correlated with optimum thera-
peutic output and central nervous system side ef-
fects. Therefore, TDM of EFV in clinical practice 
is essential for optimum therapeutic output, espe-
cially in HIV-TB co-infected patients who are un-
der treatment with the combination of EFV and 
rifampicin. 
 On the other hand, EFV possesses high protein 
binding property [>99%] and thus gets penetrated 
into male genital tract through blood. High pene-
tration in male genital tract makes it an important 
candidate to study its concentration for prophy-
laxis use. Hence, Avery et al. developed LC-
MS/MS spectrometric assay for the estimation of 
protein free and bound EFV in human seminal and 
blood plasma [131]. The first HPLC assay method 
for EFV and its hydroxyl metabolites was reported 
in 1996 by Lee et al. of Merck research laboratory, 
USA for pre-clinical studies on mouse, monkey, 
rats and dogs [132]. Thereafter, several other 
HPLC methods have been published for HPLC 
with UV and mass detectors [133-140]. 
 Techniques like DBS propose a patient-friendly 
alternative wherein blood cards are prepared by 
sampling blood from the patient with an easy sim-
ple finger prick. Thereafter, various simultaneous 
assay methods were reported in the literature for 
ARV determination form DBS using Mass and UV 
detectors [141-143]. 
 HIV replication took place inside the cell, so 
ARV drugs have to enter the cells at an adequate 
concentration to restrain viral replication. Subse-
quently, studying intracellular drug concentration 
is a valuable tool to ascertain effective levels of 
ARVs in target cells mainly in virological failure 
regardless of efficient plasma level concentrations. 
Several analytical methods for intracellular quanti-
fication of EFV on HPLC with UV and mass de-
tectors are available in recent literature [144-147]. 
Also as an alternative matrix other than plasma, 
saliva and CSF few methods are also available in 
the literature describing the EFV assays from DBS 
[148]. 
 Proustet al. separated and analysed EFV and 
other ARV drugs by RP-HPLC on a C18 column 
with spectrophotometric detection at 260 nm 
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[149]. Aymard et al. determined twelve ARV 
agents in human by validated HPLC-UV assay 
technique where separation was carried out on C18 
symmetry shield column and the analyte was de-
tected using UV detector which was set at a single 
wavelength [260 nm] [150]. Marzolini et al. simul-
taneously determined protease inhibitors IDV, 
APV, SQV, RTV, NFV and the NNRTI EFV by 
HPLC after solid-phase extraction [151]. Simi-
larly, various other simultaneous assays were re-
ported on UV detectors in which EFV was deter-
mined with rifampicin and ATVs [152-164]. 
 As the assay method with mass detectors is 
more specific, sensitive and fast, several HPLC-
MS/MS methods are also reported for EFV with 
other ARVs. Volosov et al. developed a simple 
rapid assay for estimation of ARVs including EFV 
by LC-MS/MS with a runtime of 4.5 min [165]. 
Rentsch et al. separated and detected ARVs in-
cluding EFV using LCMS and atmospheric pres-
sure chemical ionisation. Following solid-phase 
extraction, the ARVs were separated within 21 
min using gradient elution [166]. 
 Heine et al. developed and validated an RP-
HPLC assay method for the estimation of EFV. In 
this method, separation was carried out on a C18 
column with gradient elution at a flow rate of 0.25 
mL/min. The mobile phase comprised of acetate 
buffer [pH 5] and methanol and the runtime was of 
10 mins. Triple quadrupole mass spectrometer op-
erated in positive ion mode was used for fragmen-
tation and quantification [167]. Another validated 
HPLC/positive ion electrospray tandem mass spec-
trometry assay for the simultaneous estimation of 
EFV, FTC, and TDF in human plasma was re-
ported by Nirogiet al. [168]. Quaranta et al. re-
ported a fast, precise, and sensitive LC-MS/MS 
assay technique for estimation of Raltegravir 
[RAL], etravirine [ETR], EFV and 8 other ARVs 
inhuman plasma effectively implemented for rou-
tine TDM [169]. Heine et al. also developed and 
validated an assay method for rapid estimation of 
13 ARVs in plasma using LC-MS [170]. 
Etravirine [ETR] 
 ETR is diarylpyrimidine analogue approved  
by FDA in 2008 [171]. Chemically, it is an 4- 
[6-amino-5-bromo-2-[4-cyanoanilino]pyrimidin-4-
yl]oxy-3,5-dimethylbenzonitrile, the solubility of 
which in water is 0.07 mg / ml at 25 °C with logP 
value of 4.5. 
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Etravirine 
 It is a second generation NNRTI possessing 
wide range of activities that are attributed to its 
potential by binding to reverse transcriptase in 
multiple ways [171]. It possesses an extended half-
life [30-40 h] and its metabolism is catalysed by 
CYP3A4, CYP2C9, and CYP2C19 isoenzymes 
[172]. 
 With ETR being the substrate for CYP3A4, the 
possibility of drug interactions with PI is very high 
and hence it is very important to monitor the 
plasma levels of ETR. Various LC–MS/MS tech-
niques have been reported for the assay of ETR in 
human plasma. Heine et al. in 2009 developed an 
LC–MS/MS assay to estimate ETR in human 
plasma, dry blood spots, and PBMC by including 
ETR in their existing method and latter validating 
it [173, 174]. Abobo et al. reported LC–MS/MS 
estimation assay of ETR in rat plasma [175]. Sev-
eral LC–MS/MS assay techniques are also avail-
able for the simultaneous estimation of ETR with 
other NNRTIs and PIs in human plasma [176-178]. 
 A method developed by D’Avolio et al. is of 
wide interest because of the use of DBS on the 
glass filter [141]. Here, authors have developed 
and validated a new analytical technique, altering 
their previous HPLC–MS chromatographic run, 
for simultaneous estimation of nine different ARV 
drugs like PIs [SQV, ATV, APV, DRV, LPV, 
RTV] and NNRTIs [ETR, EFV,NVP] in dried 
plasma spot [179]. Also, short and long-term sta-
bility of drugs at varying storage conditions [room 
temperature, 4°C and −20°C] was reported. In this 
assay, 100 µL of plasma was used for investiga-
tion which was spread over a glass paper filter and 
drugs were extracted using tertbutylmethylether. 
After drying, the extract was reconstituted and 
chromatic separation was achieved on RP- C18 
columns and analyte were identified and quanti-
fied using quadruple mass detector. As the assay 
was validated at the concentration levels more fre-
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quently encountered in clinical practice, it is ap-
plied for routine TDM. The most significant find-
ing of this assay is the long stability of dried 
plasma spot that allows easy transfer of samples at 
room temperature for TDM and pharmacokinetic 
studies. 
Rilpivirine [RPV] 
 RPV, a diarylpyrimidine analogue, is a second-
generation NNRTI approved in 2011. Chemically 
it is an 4-[[4-[4-[[E]-2-cyanoethenyl]-2,6-dimethy- 
lanilino]pyrimidin-2-yl]amino]benzonitrile, the solu-
bility of which in water is <0.1mg/ml with logP 
value of 4.86. 
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Rilpivirine 
 It prevents the replication of HIV by directly 
binding to a hydrophobic pocket of reverse tran-
scriptase and thereby inhibits enzyme activity 
[180]. RPV possesses high protein binding prop-
erty [>99%] and hence has a long half-life and 
given in once-daily dosing [181]. 
 Various studies have evaluated the pharma-
cokinetic correlation between RPV and other 
ARVs. An important finding suggests that the in-
creased exposure of RPV when co-administered, 
RPV [150 mg]with DRV/RTV [800/100 mg] in 
once-daily dosing in 16 HIV-negative volunteers 
was due to CYP 3A4 inhibition [182]. Co-
administration of RPV [150 mg] and rifampicin 
[600 mg] in once-daily dosing in 16 HIV-negative 
volunteers for 7 days was found to diminish 
AUC24h, Cmax, and Cmin by 80%, 69%, and 89%, 
respectively for RPV [183]. Drug interactions with 
several co-administered drugs have been reported 
in the literature and hence, several analytical assay 
methods have been developed [184-192]. Studies 
revealed that RPV [150 mg] when administered 
with ketoconazole [an antifungal agent known to 
inhibit CYP 3A4 enzyme; 400 mg] in once-daily 
dosing in 16 HIV-negative volunteers resulted in 
enhancing AUC24h, Cmax, and Cmin by 49%, 30%, 
and 76%, respectively, for RPV [193]. Looking at 
all these drug-drug interactions, TDM is recom-
mended for RPV. 
 Until 2011, a single analytical assay method 
[multicomponent analysis] was reported for the 
estimation of RPV in human plasma by LC/MS 
[177]. However, the method was not precise for 
the determination of RPV and was multifaceted, 
with gradient elution, mobile phase and extended 
chromatographic run time. Also, the technique was 
not adequately sensitive for pharmacokinetic or 
bioequivalence studies. Hence, Heeswijk et al. in 
2006, Burugula et al. and Shibata et al. in 2013 
developed a single component assay method on 
LC-MS [184-186]. In the year 2013, Aouri et al. 
reported a validated assay on LC-MS/MS for the 
multicomponent analysis of RPV and EVG in 
plasma, over clinical concentrations ranges, by 
using corresponding isotopically stable-labelled 
internal standard [187]. Gupta et al. and Grégoire 
et al. in 2014 presented separately LC-MS/MS as-
say methods for routine measurement of RPV in 
plasma samples [188, 189]. Gupta et al. assay 
technique utilizes small plasma volume [50 µL] 
for processing and also employed isotopically 
stable-labelled internal standard whereas assay de-
veloped by Grégoire et al. also employed deuter-
ated-internal standard but also allows simultaneous 
determination of DTG and RPV in plasma in a 
single analysis. Cozzi et al. and Charbe et al. in 
2016 also developed and validated the HPLC-UV 
method for the simultaneous estimation of most 
commonly prescribed ARV drugs [190, 191]. 
Protease Inhibitors (PIs) 
 PIs are the class of the antiretroviral drugs 
which inhibit the protease, an enzyme essential for 
the formation of mature virions after budding out 
from the host cell membrane. Protease inhibitors 
prevent the essential steps of virion maturation i.e 
cleavage of gag and gag/pol precursor proteins 
[192]. Virions produced in which the gag/pol pre-
cursor proteins are not cleaved hence they are 
faulty and mostly non-infectious. Presently, the 
most commonly recommended PIs are LPV, IDV, 
NFV, APV and RTV, DRV and ATV. As resis-
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tance to some of the widely prescribed PIs is high, 
2nd generation PIs have been developed that are 
effective against otherwise resistant HIV variants. 
Lopinavir [LPV] 
 LPV approved in 2000 is a peptidomimetic 
HIV PI used in combination with RTV. Chemi-
cally, it is an [2S]-N-[[2S,4S,5S]-5-[[2-[2,6-
dimethylphenoxy]acetyl]amino]-4-hydroxy-1,6-
diphenylhexan-2-yl]-3-methyl-2-[2-oxo-1,3-
diazinan-1-yl]butanamide which is practically in-
soluble in water and freely soluble in methanol 
and ethanol with logP value of 5.94. 
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Lopinavir 
 LPV is exclusively metabolised by CYP3A 
[193]. LVP monotherapy does not yield effective 
concentration, however when boosted with RTV, 
plasma levels found to exceed the serum protein 
binding-adjusted 50% inhibitory concentration 
[IC50] for wild-type HIV type 1 by at least 50-fold 
[194]. The LPV-RTV combinations are available 
in capsules dosage formulation with a dose of 133 
mg of LPV and 33 mg of RTV per capsule. LPV is 
the CYP3A4 substrate whereas RTV inhibits 
CYP3A resulting in sustained and elevated plasma 
LPV levels. LPV is metabolized by CYP3A, hence 
interaction with anti-tuberculosis drugs like ri-
fampin is more likely and hence LPV is consid-
ered as a perfect compound for TDM [195]. 
 The first chromatographic simultaneous assay 
method for LPV was reported by Leibenguth et al. 
[196]. This RP-HPLC assay allows simultaneous 
quantification of six PIs [IDV, RTV, SQV, NFV, 
APV, and LPV] using carbamazepine as an inter-
nal standard. Thereafter, several simultaneous as-
says on HPLC with UV PDA, Diode array and MS 
detectors have been made available in the litera-
ture [197-216]. Although not much in use, 
Azoulay et al. in 2004 reported an immunoassay 
for LPV [217]. PIs exert their action inside cells 
where they are present in very minute quantity. 
Determination of the intracellular levels of drugs is 
an analytical challenge; overcoming this limita-
tion, few analytical methods are available in the 
literature to determine the intracellular concentra-
tions of these drugs. For routine TDM, plasma and 
saliva are the common biological matrixes, however, 
for various PIs including LPV and NNRTIs, mul-
ticomponent analytical methods based on DBS 
have been reported in the literature. TDM based on 
DBS sampling technique is not only advantageous in 
reducing the infection risk of HIV/AIDS samples 
but also allows regular mailing of patient samples. 
Indinavir [IDV] 
 IDV approved in 1996 is a synthetic hydro- 
xyaminopentane amide agent that selectively in-
hibits the protease of both HIV 1 and 2. Chemi-
cally it is an [2S]-1-[[2S,4R]-4-benzyl-2-hydroxy-5-
[[[1S,2R]-2-hydroxy-2,3-dihydro-1H-inden-1-yl] 
amino]-5-oxopentyl]-N-tert-butyl-4-[pyridin-3-
ylmethyl]piperazine-2-carboxamide which is highly 
soluble in water [0.015 mg/ml ] and ethanol with 
logP value of 2.9. 
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Indinavir 
 HIV PIs, being the substrates and inhibitors of 
CYP3A, demonstrate high probability of pharma-
cokinetic interactions with co-administered drugs 
[218, 219]. Concurrent use of PIs with CYP3A 
inducers like phenytoin ritonavir rifampin, or in-
hibitors like telithromycin, nefazodone, itracona-
zole or ketoconazole may increase the probability 
of diminished efficacy or serious drug-related side 
effects and toxicity [219]. All these possible drug-
drug interactions make IDV a good target for TDM. 
 Several HPLC assays, using UV detection, have 
been reported for the determination of IDV in se-
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rum/plasma either alone or together with its me-
tabolites [220-227]. With the aim to develop an 
assay method to analyse IDV in serum, urine, and 
cerebrospinal fluid, Svensson et al reported rapid 
and simple determination using HPLC [220]. Due 
to the higher therapeutic range, HPLC with UV or 
PDA detector is considered sensitive enough to 
quantify IDV in plasma. However, Woolf et al in 
1997 quantified IDV and deuterated IDV in human 
plasma using triple quadrapole Mass detector 
[228]. Method published in 2001 by Armbruster et 
al explains the estimation of IDV and SQV within 
the cells using an in vitro system of human umbili-
cal venous endothelial cells [229]. Various other 
simultaneous assay methods as detailed in Table 1 
have been developed for the estimation of IDV 
either alone or in combination in human blood 
plasma samples. 
Nelfinavir [NFV] 
 Approved in 1997, NFV is a synthetic antiviral 
agent that selectively inhibits HIV protease en-
zyme [230]. Chemically it is an [3S,4aS,8aS]-N-
tert-butyl-2-[[2R,3R]-2-hydroxy-3-[[3-hydroxy-2-
methylbenzoyl]amino]-4-phenylsulfanylbutyl]-
3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-
carboxamide which is slightly soluble in water and 
highly soluble in methanol, ethanol, and acetonitrile 
with logP value of 6. 
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Nelfinavir 
 NFV is primarily metabolised by CYP3A4 
[more than 50%], 2D6, 2C19, and 2C9 [231]. The 
first assay method on HPLC with UV detector re-
ported by Wu et al. did not include M8 metabolite 
[232]. Therefore, Lamotte et al. in 1999, Janoly et 
al. in 2002, Hirabayashi et al. in 2006 and Justesen 
et al. in 2013 determined NFV along with its ac-
tive metabolite M8 in human plasma using HPLC 
[233, 234]. In 2005, not much in use, automated 
microparticle agglutination immunoassay for the 
TDM of NFV was reported by Lawrence et al. 
[235]. Uglietti et al. 2007 developed an ELISA 
method which is an immunoenzymatic test based 
on the use of polyclonal rabbit antibodies [236]. In 
this study, the authors also evaluated the correla-
tion between HPLC and TDM-ELISA® results of 
NFV and M8 plasma concentrations in blood sam-
ples of HIV-positive patients treated with NFV-
containing combination therapy. Several other si-
multaneous assays of NFV with PI, NNRTI, II on 
HPLC with MASS, UV and PDA in plasma and 
DBS has been developed and discussed in Table 1. 
Amprenavir [APV] 
 APV approved in 1999 is a synthetic derivative 
of hydroxyethylaminesulfonamide that selectively 
inhibits HIV protease [237]. Chemically, it is an 
[[3S]-oxolan-3-yl] N-[[2S,3R]-4-[[4-aminophenyl] 
sulfonyl-[2-methylpropyl]amino]-3-hydroxy-1-
phenylbutan-2-yl]carbamate, the solubility of which 
in water is 40 mg/l at 25 0C with logP value of 2.2. 
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Amprenavir 
 APV is metabolised primarily by the isoenzyme 
CYP3A4 which is also the major substrate for 
various inducers and inhibitors. When prescribed 
as a mono-therapy, APV is not able to achieve 
efficient plasma levels without side effects, how-
ever as proved in a preclinical study in rats, APV 
when boosted with RTV, several fold growth in 
the area under the curve from 0 to 8 h [AUC0–8] 
of APV was observed. Similarly, when APV was 
co-administered in humans with CYP3A4 inhibi-
tors [e.g. ketoconazole], the surge in the AUC of 
APV was observed [238]. 
 At the suggested dose, APV is effective in re-
ducing the seminal and blood plasma load of HIV 
but studies revealed that it exhibits limited access 
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to CNS and into the male genital tract [239]. A 
better study on the ARV drug distribution into 
male genital tract could help formulate the effec-
tive drug and dose regime not only to reduce the 
viral load but also to reduce the sexual transmis-
sion [240, 241]. Therefore, Pereira et al. developed 
a method for the determination of APV in human 
seminal plasma using HPLC–tandem MS whereas 
Sparidans et al. developed a sensitive LC assay for 
APV in human plasma, cerebrospinal fluid and 
semen [242, 243]. 
 In the year 2007, to quantify the drugs like LPV 
and RTV in plasma and PBMC’s, an immune as-
say based ELISA method was developed [217]. In 
2007, Bastiani et al. developed and evaluated an 
immunoassay for the monitoring of APV [244]. In 
this assay, a diazo-conjugate of APV and bovine 
serum albumin was utilized to evoke polyclonal 
anti-APV rabbit sera, which were then used in a 
competitive ELISA assay carried out in mi-
croplates coated with the anti-APV polyclonal an-
tibodies via a capture anti-rabbit antibody. The 
competition between free APV and a conjugate of 
the drug with horseradish peroxidase allowed the 
development of a fast and easy to use ELISA 
[244]. 
 Two individual methods for assaying APV in 
human plasma, cerebrospinal fluid semen and in 
human seminal plasma using LC-MS/MS are 
available [242, 243]. Several other simultaneous 
HPLC assays with UV detection, photodiode, 
PDA, and MS have been reported in the literature 
[244-250]. Marzolini et al. developed and vali-
dated a HPLC method for the simultaneous quanti-
fication of IDV, APV, SQV,RTV, NFV, and EFV 
from the plasma of HIV infected patient with UV 
detector set at 201 nm [151]. Various simultaneous 
methods have been reported for APV with other 
ARVs, which mostly use UV or MS detection sys-
tem. Proust et al. separated six ARV agent by re-
versed-phase LC on a C18 column with spectro-
photometric detection at 260 nm [156]. 
 Monitoring drug concentrations inside the cell 
at the target proteins is used to guarantee the 
therapeutically effective levels is important par-
ticularly in case of virological failure regardless of 
effective drug concentrations. Hence, few simulta-
neous assay methods for ARV quantification from 
PBMC have been reported in the literature for ex-
ample, Elens et al. proposed a UPLC–diode array 
detection assay for the simultaneous quantification 
of the PIs like APV, ATV, IDV, LPV, NFV, RTV, 
SQV, and TPV [TPV], and NNRTIs like EFV and 
NVP [79, 144, 145, 204]. Similarly, Djerada et al. 
useed UPLC-MS/MS, to concurrently quantify 
EVG, RAL, MVC, etravirine, TDF and 10 other 
ARV agents [APV, ATV, darunavir, EFV, IDV, 
LPV, NVP, RTV, SQV, TPV] and boceprevir 
[215]. 
Saquinavir [SQV] 
 SQV approved in 1995 is a peptidomimetic in-
hibitor of HIV protease enzyme. Chemically it is 
an [2S]-N-[[2S,3R]-4-[[3S,4aS,8aS]-3-[tert-butyl- 
carbamoyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-
isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-
2-[quinoline-2-carbonylamino]butanediamide 
which is insoluble in water but soluble in DMSO 
with logP value of 3.8. 
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Saquinavir 
 SQV is a decent substrate for CYP3A isozymes 
and is utilized as part of a combination with RTV 
for the treatment of HIV. SQV is also the good 
inhibitors and substrates for p‐glycoprotein [250-
252]. As bioavailability of SQV is not sufficient 
for a therapeutic response without side effects, it is 
generally boosted by RTV at a lower dose. On the 
drug interaction front, any drug, inducing 
CYP3A4 activity can stimulate SQV metabolism 
and could reduce its plasma levels [253, 254]. For 
example, Rifampin is the potent inducer of 
CYP3A4 and hence could reduce AUC of SQV by 
around 80 %. Rifabutin, which is also a known 
cyp3A4 inducer, could exert a similar effect and 
could reduce AUC of SQV by 40 %. Other 
CYP3A4 inducers like phenobarbital, phenytoin, 
dexamethasone, and carbamazepine were also 
found to reduce the SQV concentration in patient 
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plasma [255]. Contrary to this, drugs like keto-
conazole and Grapefruit juice, which are known 
inhibitors of the CYP450 may increase the AUC 
of SQV [256]. Infact, Grapefruit juice was found 
to increase the AUC of SQV by around 220% 
[257]. All these drug-drug interactions make SQV 
an ideal candidate for TDM. 
 Various analytical methods were developed for 
clinical monitoring for SQV. Knebel et al. devel-
oped and validated HPLC-MS assay method for 
the determination of SQV in human plasma. Use 
of MS detector enables Knebel et al. to quantify 
SQV in the linear range from 0.4 to 200 ng/ml 
[258]. SQV was then later determined by 
Hoetelmans et al. in human plasma, saliva and 
cerebrospinal fluid by ion-pair HPLC-UV and by 
Ha et al. in plasma by HPLC-UV [52, 259]. Frap-
pier et al. developed a simultaneous quantification 
method for the determination of RTV and SQV in 
human serum by HPLC [260]. Armbruster et al. 
performed a series of experiments on HPLC-UV to 
determine intracellular levels of IDV and SQV, 
using an in vitro model of human umbilical venous 
endothelial cells. In this experiment, Armbruster et 
al. also evaluated the influence of these agents on 
the expression of adhesion molecules on these 
cells [229]. 
 Strategies depicted here for the estimation of 
SQV involved tiresome and lengthy sample 
preparation like liquid–liquid or solid–liquid 
extraction. Such methods not only require a higher 
time of extraction but are also expensive as 
compared to the other available methods. 
Considering this, Campanero et al. developed a 
bio-analytical assay using HPLC to quantify SQV 
plasma concentrations in a short period of time 
[261].  The oral bioavailability of SQV is around 4% 
after a meal and even lower when taken in the 
fasted state. The low oral bioavailability of SQV is 
attributed to fast metabolism, rapid first-pass clear-
ance and poor transport across the intestinal 
mucosa [262]. 
 To study the effects of all the parameters which 
affect the oral bioavailability of SQV, Ucpinar et 
al. developed and validated an HPLC-UV assay 
method for the in-vitro quantification of SQV 
using Caco-2 cell monolayer as a model [263]. 
Plasma is considered for routine TDM of PI and 
NNRTIs whereas saliva is considered as the alter-
native body fluid for determining the plasma con-
centration. 
 For the first time, Koal et al. developed an LC-
MS/MS method for simultaneous multicomponent 
analysis of PI’s and NNRTI’s including SQV in 
dried blood [142]. 
 As the bioavailability of SQV is very low, two 
HPLC–UV assays were developed with a detec-
tion limit close to 1 ng/mL plasma. Few studies 
have shown simultaneous quantification of SQV 
with other PIs with higher limits of quantification 
[264, 265]. In addition, SQV was also simultane-
ously assayed with the NNRTI’s like delavirdine 
and EFV [149, 151]. Other important methods like 
immunoassay and LC–MS/MS for the simultane-
ous quantification of SQV have been developed 
[266]. The HPLC–UV assay [limit of quantifica-
tion 1 ng/mL] was compared with a radioimmuno-
assay [LOQ 0.5–1.0 ng/mL] and validated against 
an LC–MS–MS assay [LOQ 0.4 ng/mL] [266, 
267]. The LC–MS/MS assay used solid-phase ex-
traction [SPE] for sample cleaning and separation 
was carried out on a short LC column in the se-
lected reaction monitoring mode [SRM]. The as-
say was validated and is useful to determine the 
SQV in range of 0.4–200 ng/mL. An isotopically 
labelled form of SQV was used as the internal 
standard to normalize the possible sample loss dur-
ing extraction. Another highly useful assay for low 
level determination of SQV in plasma, urine, and 
saliva samples using LC-MS/MS was reported in 
1997 and 2003 [259, 268]. 
Ritonavir [RTV] 
 RTV, a peptidomimetic agent useful in inhibit-
ing both HIV-1 and HIV-2 proteases, was ap-
proved as monotherapy, or for co-administration in 
patients with advanced HIV infection [269]. 
Chemically, it is an 1,3-thiazol-5-ylmethyl N-
[[2S,3S,5S]-3-hydroxy-5-[[[2S]-3-methyl-2-[[methyl-
[[2-propan-2-yl-1,3-thiazol-4-yl]methyl]carbamoyl] 
amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]car- 
bamate which is insoluble in water but freely soluble 
in methanol and ethanol and isopropanol with logP 
value of 3.9. 
 Although, RTV was developed as a PI, it was 
later found to be a very potent inhibitor of 
CYP3A4 and CYP2D6 hence nowadays, it is used 
as a pharmacokinetic booster to boost the plasma 
levels of other PIs mostly metabolised by these 
isoenzymes [270]. 
 A bioassay method for the quantification of 
RTV in human samples was first briefly described 
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by Hsu et al. [271]. Later, an assay method was 
reported by Marsh et al. of Abbott Laboratories to 
determine RTV concentration in biological sam-
ples using HPLC, whereas Hoetelmans et al. pub-
lished an HPLC method for the determination of 
RTV in human plasma, cerebrospinal fluid, and 
saliva [272, 273]. Granda et al. modified a previ-
ously described method and applied it for the de-
termination of RTV concentrations in human 
plasma and in mouse serum, liver, and brain [272, 
274]. Penzak et al. in 2001, developed a rapid 
HPLC assay for the quantitation of RTV in human 
plasma [275]. 
 Intracellular concentrations of ARV drugs are 
not only influenced by their physical and chemical 
properties but patient genetic also plays important 
role in the proper therapeutic outcome. The as-
say’s quantifying PIs and NNRTIs levels at the 
site of their pharmacological action are an essen-
tial tool for the on-going therapeutic drug monitor-
ing aimed at averting ARV therapy failure and 
toxicity. Few such simultaneous assay methods 
have been reported in the literature which deter-
mines the intracellular concentration of ARVs 
along with RTV [147, 276]. 
 Akeb et al. in 2002 described the first one-step 
competitive ELISA for RTV quantification using 
RTV–acetylcholinesterase as a tracer [277]. This 
method demonstrated 15 times lower threshold 
sensitivity than HPLC–UV and permitted sensitive 
routine determination of RTV in methanol-
extracted plasma and from HIV patients receiving 
multidrug therapy. Frappier et al. reported simul-
taneous quantification method for RTV and SQV. 
This method involved extraction of RTV and SQV 
from serum on solid-phase extraction using C18 
cartridges followed by HPLC separation on C8 
column with a UV detector set at 240 nm [260]. 
Several other sensitive simultaneous assay meth-
ods were reported with UV and MS detectors for 
RTV [202, 205, 209, 211, 264, 265, 278]. 
Atazanavir [ATV] 
 Approved in 2003, ATV is an aza-dipeptide 
analogue with a bis-aryl substituent on the [hy-
droxethyl]hydrazine moiety useful against wild 
and mutant forms of HIV protease [279]. Chemi-
cally it is an methyl N-[[2S]-1-[2-[[2S,3S]-2-
hydroxy-3-[[[2S]-2-[methoxycarbonylamino]-3,3-
dimethylbutanoyl]amino]-4-phenylbutyl]-2-[[4-
pyridin-2-ylphenyl]methyl]hydrazinyl]-3,3-dimethyl-
1-oxobutan-2-yl]carbamate which is slightly soluble 
in water but freely soluble in methanol and ethanol 
with logP value of 4.5. 
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Atazanavir 
 ATV is not only a substrate and inhibitor of 
CYP P450 3A but is also an inhibitor and inducer 
of transporter protein like P-glycoprotein [280]. 
Hence to avoid the drug interactions, ATV has to 
be used with care in patients taking strong and 
moderate CYP3A4 substrates, inhibitors and in-
ducers. Because of the possible drug-drug interac-
tion and common disposition enzymes involved, 
ATV is considered as the major TDM target in 
ART. The first ATV plasma assay was reported by 
Schuster et al. whereas Jemal et al. of Bristol-
Myers Squibb Pharmaceutical Research Institute, 
USA developed an assay for ATV quantification 
in PBMC [281, 282]. Colombo et al., reported a 
simple ATV assay for quantification in human 
plasma using offline solid-phase extraction fol-
lowed by separation using HPLC, which was cou-
pled with UV-diode array detector [283]. Spari-
dans et al. developed an isocratic LC-UV method 
dedicated to ATV with a sample pre-treatment 
[284]. Cateau et al. determined ATV levels in hu-
man plasma using solid-phase extraction and 
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Ritonavir 
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HPLC [285]. Loregian et al. in 2006, Cattaneo et 
al. in 2008 and Muller et al. in 2010 developed a 
simple HPLC-UV method for ATV determination 
in human plasma [286-288]. 
 As mentioned previously, serum and especially 
plasma are the preferred matrices whereas saliva is 
considered as an alternative body fluid for TDM 
[289]. TDM using DBS samples is advantageous 
as compared to plasma because it reduces the risk 
of infection to a minimum and also enables regular 
mailing of blood samples and easy handling in pa-
thology. Considering this, Koal et al. in 2005, 
D’Avolio et al. in 2010 and recently Watanabe et 
al. in 2014 quantify ARV drugs including ATV in 
DBS samples using LC-MS/MS [141, 142, 216]. 
 Fayet et al. developed a method to determine 
unbound ARV drug concentrations. This method is 
useful for the assessment of inter-individual vari-
ability in ARV drug-free fractions and their corre-
lation with albumin and glycoprotein levels in pa-
tients with HIV undergoing TDM [290]. 
 Intracellular levels of ARV drugs are not only 
influenced by their physical and chemical proper-
ties but patient genetic factors are actively in-
volved in maintaining the drug levels inside the 
cells [291, 292]. Therefore, assays measuring 
ARV levels at the site of their pharmacological 
action appear to be an essential tool for accurate 
TDM. Such assay methods describing the mono-
nuclear blood cell concentration were first devel-
oped by Colombo et al. in 2005 and later by 
D’Avolio et al. in 2011 and Podany et al. in 2014 
[79, 145, 147]. 
 Other than the above-mentioned methods for 
ATV, several other simultaneous assay methods 
on HPLC with UV Diode array and PDA detectors 
are available in the literature [200-203, 293]. MS 
detectors are considered to be highly sensitive and 
LC-MS assays are fast and suitable for high-
throughput TDM. Hence, several simultaneous 
chromatography assay methods have been devel-
oped for ARTs including ATV with MS detection 
systems [169, 170, 177, 179, 246, 249, 294]. 
Darunavir [DRV] 
 DRV was designed to overcome high genetic 
barrier to the development of resistance [295]. 
Chemically, it is an [[3aS,4R,6aR]-2,3,3a,4,5,6a-
hexahydrofuro[2,3-b]furan-4-yl] N-[[2S,3R]-4-[[4-
aminophenyl]sulfonyl-[2-methylpropyl]amino]-3-
hydroxy-1-phenylbutan-2-yl]carbamate, the solubil-
ity of which in water is 0.15 mg/mL at 20 °C but is 
freely soluble in methanol with logP value of 1.8. 
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Darunavir 
 Several studies have shown that DRV is useful 
against wild-type HIV-1 and PI-resistant viruses 
[295, 296]. Co-administration of DRV is with low-
dose RTV [DRV/r]; the 600/100 mg twice daily 
dose has now been approved in many countries for 
treatment-experienced adult patients, such as those 
with HIV-1 strains resistant to more than one PI 
whereas 800/100 mg qd dose is now recommended 
for naive patients [297]. DRV has an intermediate-
to-high absorptive permeability in Caco-2 mono-
layers, indicating that DRV exhibits sufficient 
membrane permeability to obtain adequate intesti-
nal absorption. DRV was found to bind 95% to α1- 
acid glycoprotein and was also shown to bind to 
albumin, but to a lesser extent than to α1- acid 
glycoprotein [298]. 
 Results from an in-vitro study of human liver 
microsomes indicate that DRV primarily under-
goes oxidative metabolism and is extensively 
metabolised by CYP450 enzymes, mainly CYP3A 
[297, 298]. DRV is metabolised by and also inhib-
its CYP3A. However, in combination with RTV, a 
more potent inhibitor of CYP3A, there is a marked 
increase in DRV plasma concentrations. In a study 
of HIV-negative healthy volunteers, the absolute 
bioavailability of DRV [600 mg once daily] was 
increased to 82% in the presence of RTV [100 mg 
twice daily] compared with 37% when DRV was 
administered alone [299]. 
 The t1/2 [terminal elimination half-life] of DRV, 
when combined with RTV [1,200/100 mg once 
daily] in a dose-ranging study of healthy volun-
teers was found to be 15 h [4]. Following intrave-
nous administration of DRV [150 mg; single 1 h 
infusion] alone or in the presence of low-dose 
RTV [100 mg twice daily] in HIV-negative 
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healthy volunteers, the mean systemic clearance 
was 32.8 l/h and 5.9 l/h, respectively [299]. 
 Various simultaneous and mono-component 
assays have been published to quantify DRV in 
different biological matrices. Other ARV drugs 
assayed with DRV include other PIs, NRTI and 
NNRTI, integrase inhibitor, RAL and an entry in-
hibitor, MVC [299-302]. DRV was assayed in 
cerebrospinal fluid and human plasma with a limit 
of quantitation ≥5.0 ng/mL. DRV and RTV were 
assayed in human plasma using tandem mass  
spectrophotometer with a sensitivity of 10 ng/mL 
[300-302]. 
 Another important simultaneous assay was de-
scribed to quantify RTV, ETR,ABC and DRV 
[178]. Simple liquid-liquid extraction in tert-butyl 
methyl ether was employed to extract DRV from 
100µL of plasma. The separation was carried out 
in 7 mins on a column having 2µm particle under 
gradient elution. This method was further vali-
dated for the plasma concentration range of 2–
2000 ng/mL [178]. To study drug-drug interac-
tions, Fayet et al. developed a simultaneous assay 
for DRV and three new ARV agents namely RAL, 
MVC, and ETR [176]. Few other simultaneous 
methods for the determination of DRV along with 
six or more ARVs in DBS, human plasma and 
PBMCs [intracellular concentration] by LC–MS/ 
MS were also published [79, 141, 174, 177, 249]. 
 Considering the convenience of DBS, Heine et 
al. developed a simultaneous assay to quantify 
four PIs and two NNRTIs from DBS [174]. Few 
other more sensitive simultaneous assay methods 
were developed to quantify DRV and most com-
monly prescribed ARV’s from blood plasma sam-
ples with ≥15 ng/mL LOQ [141, 177, 249]. To 
quantify DRV and other ARV’s at the site of ac-
tion, Heine et al. simultaneously assayed nine PIs, 
NFV metabolite and two NNRTs in lysate of 
PBMC’s. [173] Another highly sensitive simulta-
neous HPLC–MS assay for various ARV’s includ-
ing DRV in PBMC of HIV infected patients was 
developed [79,147]. The LOQ of all the ARV 
ranged from 0.1 to 32 ng/mL. The separation was 
carried out for 15 mins on Atlantis T3 C18 column. 
Due to the large number of samples, robust assays 
with short run time are in demand, hence, Gupta et 
al. published short and robust UPLC–MS/MS as-
say for DRV determination in human plasma sam-
ples [303]. On the same line, Djerada et al. devel-
oped and validated a simple robust method for 
TDM of 15 ARVs on UPLC-MS/MS [215]. Very 
recently, Watanabe et al. also developed another 
sensitive UPLC–Mass assay for the quantification 
of HIV PIs from DBS sample [216]. 
Tipranavir [TPV] 
 TPV approved in 2005 is a non-peptidomimetic 
agent that inhibits wild and drug resistant forms of 
HIV protease [304]. Chemically, it is an N-[3-
[[1R]-1-[[2R]-4-hydroxy-6-oxo-2-[2-phenylethyl]-2-
propyl-3H-pyran-5-yl]propyl]phenyl]-5-[trifluoro- 
methyl]pyridine-2-sulfonamide, the solubility of 
which is insoluble in water but soluble in dehydrated 
alcohol with logP value of 6.9. 
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Tipranavir 
 TPV is typically a substrate of CYP3A4 and 
hence for effective plasma concentration in 
plasma, TPV 500 mg is commonly boosted by 200 
mg of RTV [305]. The combination of TPV with 
RTV has inducing and inhibiting effects on several 
CYP isoenzymes [306]. As a result, drug interac-
tions are more common with these combinations 
which essentially make TPV an ideal candidate for 
TDM. 
 To study the TPV drug interactions and TDM, 
Crommentuyn et al. were the first group who pub-
lished a simultaneous assay to quantify TPV with 
ATV using tandem MS detector coupled with LC 
[294]. Typically, TPV clinically significant plasma 
concentration ranges between 1 and 50 mg per 
millilitre and hence it does not need very highly 
sensitive assay. Therefore, Keil et al. , Giraud et 
al., Dailly et al. and Colombo et al. separately in 
2006 and D’Avolio et al. in 2007 reported HPLC-
UV assay for TPV [307-311]. In 2008, Langmann 
et al. developed another HPLC-UV method for the 
determination of TPV in plasma [312]. Several 
other simultaneous quantification assay methods in 
various biological matrixes on HPLC coupled with 
mass, UV, fluorescence detectors have been men-
tioned in various literature and details of the same 
are given in Table 1. 
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ENTRY INHIBITORS AND FUSION 
INHIBITORS 
 Entry inhibitors [EI’s] work by preventing the 
HIV entry in healthy CD4 cells [313]. Entry in-
hibitors work by blocking CCR5 or CXCR4 recep-
tor proteins of CD4 cells or GP120 or GP41 pro-
teins on the HIV surface [314]. In order to get en-
try into the CD4 cells, GP120 or GP41 proteins 
present on the HIV surface must dock with the 
CCR5 receptor proteins present on the CD4 cells. 
EI’s essentially work by preventing this to occur. 
Some EI’s block gp120 or gp41 proteins whereas, 
some work by blocking CCR5 or CXCR4 recep-
tors on a CD4 cell's surface [315]. Successful 
blocking of these entry assisted proteins makes 
binding of HIV with the surface of CD4 cells dif-
ficult and ultimately prevent the HIV entry into the 
immune cells [316]. Two entry inhibitor’s, Roche's 
Fuzeon [enfuvirtide, ENF: targets the gp41 protein 
on HIV's surface] and Pfizer's Selzentry [MVC: 
targets CCR5 protein on CD4 cells] have been ap-
proved by the U.S. Food and Drug Administration 
[FDA] in March 2003 and August 2007, respec-
tively. 
Enfuvirtide [ENF] 
 ENF is a high molecular weight polypeptide 
made up of 36-amino acid [317]. Although HPLC 
and UPLC coupled with UV, Mass etc detectors 
are the techniques of choice to quantify a large 
number of drugs from various biological matrices. 
Quantification of peptides like ENF on HPLC col-
umns is a difficult task. Challenges like column 
blocking, sample extraction, sticking to tubing and 
container walls and limited separation limit HPLC 
use in TDM of ENF. Assays for such peptides 
usually depend on the automated immune assays. 
With all the challenges, Lawless et al. and Chang 
et al. of Hoffmann-La Roche, USA successfully 
developed an assay for ENF and its metabolite in 
human plasma using LC–MS/MS and HPLC with 
fluorescence detector respectively [318, 319]. 
Maraviroc [MVC] 
 MVC which was approved in 2007 is a 
chemokine co-receptor 5 [CCR5]antagonist. 
Chemically it is an 4,4-difluoro-N-[[1S]-3-[[1S, 
5R]-3-[3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl]-
8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl] 
cyclohexane-1-carboxamide which is fairly solu-
ble in water and methanol with logP value of 5.1. 
It is used in combination with other anti-HIV 
drugs for the treatment of HIV-1 infection. 
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Maraviroc 
 It works by inhibiting the entry of HIV into 
CD4 cells by blocking CCR5 receptor on CD4 
cells [320]. MVC undergoes N-dealkylation and 
oxygenation before excretion [321]. N-
dealkylation is chiefly facilitated by CYP3A4 
which is also involved in the metabolism of sev-
eral drugs of different category thereby making 
MVC an important candidate for TDM [322]. 
 To facilitate TDM and drug interaction studies 
of MVC, Fayet et al. and Martin et al. in 2009 
separately reported the assays to quantify MVC 
using LC-MS/MS with other commonly prescribed 
ARV drugs [RAL, MVC, DRV, and ETR] [176, 
249]. Notari et al. reported a simple simultaneous 
assay to quantify MVC and RAL in human plasma 
samples using HPLC-UV [323]. Avolio et al. de-
veloped and validated an efficient simple HPLC-
UV assay to quantify MVC in the plasma sample 
of HIV infected patients [324]. On a similar line, 
Takahashi et al. validated a robust LCMS assay to 
determine plasma MVC levels in human blood 
plasma samples [325]. The principal benefit of 
Takahashi’s assay is the rapid liquid-liquid sample 
extraction from plasma and the use of an internal 
standard to normalize the sample loss. 
 In 2010, Else et al. developed and validated a 
fast and sensitive LC–MS/MS assay for simulta-
neous quantification of PI’s like APV, ATV, 
DRV, LPV, RTV, SQV, NNRTI’s like NVP, 
CCR5 antagonists like MVC and the “second gen-
eration” NNRTI’s like ETR and RPV [177]. For 
sample extraction, IS [quinoxalone; QX] was 
added to 100µl plasma aliquots prior to protein 
precipitation. 500 µl of acetonitrile [500µl] and 
0.05% formic acid were used for the protein pre-
cipitation. Analyte separation was achieved on a 
reverse-phase C18 column with gradient elution 
[acetonitrile and 0.05% formic acid]. All the ana-
lytes including IS were identified and quantified 
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by operating triple-quadrupole in selective reaction 
monitoring and positive ionisation mode. 
 To extend the study of distribution of MVC to 
various body compartments, Brewer et al. of 
Pfizer, UK developed and validated an assay to 
quantify MVC in human plasma, urine, and cere-
brospinal fluid [326]. This assay comprises of the 
simple protein precipitation extraction followed by 
LCMS using TurboIon- Spray® and multiple-
reaction monitoring. This assay was also validated 
to quantify one of the major metabolites of MVC’s 
[UK-408,027] in plasma. MVC-d5 was used as an 
internal standard. The assay enabling the meas-
urement of IIs, PIs and NNRTIs concentration at 
the site of the pharmacological action is an essen-
tial tool for preventing ARV therapy failure and 
drug-related side effects and toxicity. Thus, to 
determine the exact intracellular levels of ARV, 
D’Avolio et al. in 2011 came up with the article, 
titled as “A HPLC–MS method for the simultane-
ous quantification of fourteen ARV agents in pe-
ripheral blood mononuclear cell of HIV infected 
patients optimized using medium corpuscular vol-
ume evaluation”. This assay was highly sensitive 
and selective to determine the simultaneous quan-
tification of14 ARV drugs in PBMC’s for HIV-
infected [79]. PBMCs were isolated by Ficoll den-
sity gradient centrifugation. Drugs from PBMC’s 
pellets were extracted with methanol: water [70: 
30, v/v], and quinoxaline was used as an IS. The 
supernatant obtained was dried and resuspended in 
water/acetonitrile [60/40, v/v], before separation 
on 2.1 mm × 150 mm Atlantis® T3 3µ chroma-
tographic column. Chromatographic separations 
were performed using gradient elution. Analyte 
quantification was performed using electro-spray 
ionisation–single quadrupole MS operating in se-
lected ion recording [SIR] detection mode. 
 PIs [IDV, SQV, NFV, NFV M8 metabolite, 
APV, DRV, ATV, RTV, LPV, TPV] integrase in-
hibitor [II] [RAL] and the NNRTIs [NVP and 
ETR] were identified in positive ionisation mode, 
while EFV was quantified in negative ionisation 
mode. The calibration curves were obtained using 
blank PBMCs spiked with ARV drugs at concen-
trations ranging from 0.1 to 32 ng/mL [1–320 
ng/mL for TPV] and fitted to a quadratic regres-
sion model weighted by 1/X. 
 To reduce the time of analysis and solvent con-
sumption in 2013, Djeradaet al. developed UPLC-
MS/MS assay for simultaneous analysis of EVG, 
RAL, MVC, ETV, TFV, boceprevir and 10 other 
ARV agents in human plasma samples [215]. Very 
recently in 2014, Simiele et al. published new 
HPLC-MS assay to determine MVC plasma levels 
[327]. In this assay 6,7-Dimethyl-2,3-di[2-pyridyl] 
quinoxaline was used as an internal standard and 
added to 100 µL of plasma. Protein precipitation 
method to extract the analyte from the sample was 
employed. Protein precipitation of plasma sample 
was carried out using 500 µL of acetonitrile. All 
the analyte was separated on a T3 Atlantis column 
[150 mm × 4.6 mm] with a particle size of 5 µm. 
Fragment Ions were detected at m/z 257.5 and 
313.3 for MVC and quinoxaline respectively. 
INTEGRASE INHIBITORS [II’S] 
 II’s also known as integrase strand transfer in-
hibitors (INSTIs), are a class of ARV drugs devel-
oped to block the action of an important enzyme 
called integrase. Integrase is a viral enzyme that 
facilitates the insertion of the viral genetic material 
into the DNA of the CD4 cell [328]. Since integra-
tion is an important step in replication, blocking it 
can stop further formation and spread of the virus. 
II’s were originally developed for the treatment of 
HIV infection, but later found their use in the other 
retrovirus infections. Since II’s target a distinct 
and important phase in the retroviral life cycle, 
they may be very good candidates in combination 
therapy to minimize drug development resistance. 
Raltegravir [RAL] 
 RAL which was approved in 2007 is a pyr-
rolidinone derivative used in combination with 
other anti-HIV agents [329,330]. Chemically, it is 
an N-[2-[4-[[4-fluorophenyl]methylcarbamoyl]-5-
hydroxy-1-methyl-6-oxopyrimidin-2-yl]propan-2-
yl]-5-methyl-1,3,4-oxadiazole-2-carboxamide which 
is soluble in methanol with logP value of 0.4. 
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Raltegravir 
 Other than the P-gp substrate, the major 
mechanism of clearance of RAL in humans is 
UGT1A1-mediated glucuronidation [331, 332]. 
Being the first member of its class and substrate 
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for SLC22A6 and P-gp, RGV is considered as an 
important candidate for TDM. 
 The first RAL assay was on HPLC-MS/MS 
which was reported by Merschman et al. [333]. As 
the assay developed by Merschman et al. was in-
tended for clinical studies at Merck, this method 
was not easily transferable to routine clinical prac-
tice because of the use of stable radioisotope of 
RAL and mass detector. To overcome this issue, 
Poirier et al. and Goldwirt et al. separately came 
up with the simple method for the quantification 
RAL in human plasma samples using HPLC with 
fluorescence detection, whereas Long et al. pub-
lished a sensitive HPLC-MS assay for RAL analy-
sis [334-336]. 
 Poirier et al. and Merschman et al. used a 
similar liquid–liquid extraction method which was 
not easily available in all the bio-analytical labora-
tories. There was still a need for a standard univer-
sal assay that can be applied to bio-analytical labo-
ratories globally. Therefore in 2008, Rezk et al. 
developed and validated an accurate and precise 
HPLC-UV method for rapid determination of RAL 
in human blood plasma after solid phase extraction 
[337]. 
 As described previously, with an added advan-
tage of DBS sampling, Heine et al. developed and 
validated the simple assay for the quantification of 
RAL in plasma, DBS and PBMC lysate by means 
of LC-MS/MS [338]. This assay is very handy for 
the pharmacokinetic studies in children and neo-
nates and also enables self-sampling for purposes 
of TDM. 
 Prophylactic use of RAL depends on its capac-
ity to hoard in the secretion of reproductive or-
gans. Therefore, to be an effective pre- and post-
exposure prophylaxis agent against HIV infection, 
the pharmacokinetics of RAL in female genital 
tract secretions is needed to be understood. To 
support the PK studies of RAL in female genital 
tract secretion, Talameh et al. developed an HPLC 
assay to quantify RAL in CVF using a previously 
validated solid-phase extraction assay [337, 339]. 
In 2012, Robbins et al. developed and validated 
UPLC-MS assay to quantify RAL in human 
plasma and similarly, Jean-Francois et al. devel-
oped a simultaneous assay to quantify azole anti-
fungals, antibiotics, imatinib, and RAL in human 
plasma by two-dimensional HPLC-MS [340, 341]. 
MS is an expensive and chromatographic method 
generally requiring time-consuming extraction and 
clean-up steps prior to chromatographic separa-
tion. To overcome this issue, Peris-vicente et al. 
developed a micellar liquid chromatography assay 
for the determination of ABC, 3TC and RAL in 
plasma which does not need tedious and time-
consuming extraction clean-up steps to develop a 
well-resolved chromatogram [342]. 
 Another very useful UPLC-MS/MS method 
was developed by Djerada et al. for the determina-
tion of the commonly prescribed PI’s like APV, 
ATV, DRV, IDV, LPV, RTV, SQV and TPV, 
TDF a NRTI, non-NRTI such as EFV, NVP, ETR, 
MVC RAL, EVG and direct acting anti-HCV 
boceprevir [215]. Several other simultaneous assay 
methods for RAL are mentioned in Table 1. 
Elvitegravir [EVG] 
 EVG, approved in 2012 is a modified quinolone 
antibiotic with activity against HIV1. Chemically 
it is an 6-[[3-chloro-2-fluorophenyl]methyl]-1-[[2S]-
1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-
oxoquinoline-3-carboxylic acid which is slightly 
soluble in water but highly soluble in methanol with 
logP value of 5.3. 
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Elvitegravir 
 It is prescribed as a combination in a once-daily 
single-tablet regimen, compromising 150 mg of 
EVG, 150 mg cobicistat, 200 mg FTC, and 300 
mg TDF disoproxilfumarate [TDF] [343]. Cobistat 
being the CYP3A inhibitor, acts as a pharmaco-
enhancer to boost the effective plasma levels of 
EVG [344]. EVG is primarily metabolised by 
CYP3A4 and a small part of EVG is also metabolised 
via glucuronidation mediated by UGT1A1 [345]. 
In a 10-day monotherapy study which was per-
formed in patients with HIV infection EVG 800 
mg/day, 200, 400 and 800 mg twice daily and 50 
mg boosted with RTV 100 mg/day provided a 
maximum mean change of viral load from baseline 
[346, 347]. 
 The drug interactions between AZT, dida-
nosine, d4T, ABC, ETR and RTV-boosted EVG 
were studied. The results showed that these drugs 
can be co-administered regardless of dose adjust-
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ment [348, 349]. A comparative study of EVG/ 
cobicistat/ FTC/TDF disoproxilfumaratevs EFV/ 
FTC/TDF disoproxilfumarate in the treatment of 
naïve patients showed that 90 and 83% of patients 
attained a virus load lower than 50 copies/mL at 
24 and 48 weeks, respectively. Psychiatric side 
effects were observed in the EVG/ cobicistat/FTC/ 
TDF disoproxilfumarate group when compared 
with that of the EFV/FTC/TDF disoproxilfumarate 
arm [350]. Effect of the protein-rich drink or a 
standard meal on the pharmacokinetics of the 
EVG, Cobicistat, FTC and TDF in healthy Japa-
nese male subjects was studied by Ishikawa et al. 
[351]. Authors observed that the EVG and TDF 
component of the combination was found to de-
crease by 50% and 28%, respectively when admin-
istered in a fasted state whereas the EVG and TDF 
levels were comparable following administration 
with a nutritional protein-rich drink and with a 
standard breakfast. Food or a nutritional drink, on 
the other hand, did not lower the bioavailability of 
Cobicistat or FTC. 
 As co-morbidities like dyslipidemia are an im-
portant factor to be considered in ART, a study 
was conducted on an interaction between cobi-
cistat induced EVG and antilipidemic agent Rosu-
vastatin [352]. The study revealed that although 
the rosuvastatin concentrations increased when co-
administered with EVG/co, no clinically relevant 
interactions were observed between EVG/co and 
rosuvastatin. 
 Risk of lower exposure to EVG even when 
boosted with RTV has to be considered in associa-
tion with drugs or environmental factors that 
strongly induce CYP3A activity. Hence monitor-
ing EVG plays the crucial role in the success of 
ART. An assay for EVG using an SPE has been 
reported as a part of clinical studies, however, with 
a limited calibration range [only up to 1000 ng/ml] 
and without much details of the validation [353]. 
To date, two simultaneous assays are available in 
the literature for the quantifications of EVG which 
can apply for routine TDM service for patients fol-
low-up and for clinical research projects [187, 215]. 
Dolutegravir [DTG] 
 DTG is an HIV integrase strand transfer inhibi-
tor approved by FDA in 2013. Chemically it is an 
[4R,12aS]-N-[[2,4-difluorophenyl]methyl]-7-
hydroxy-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-
2H-pyrido[5,6]pyrazino[2,6-b][1,3]oxazine-9-
carboxamide which is slightly soluble in water but 
highly soluble in methanol with logP value of 2.2. 
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 It is the first second-generation approved drug 
that blocks the enzyme integrase necessary for 
HIV viral replication. DTG can be used for treat-
ing HIV patients who have either taken [treatment-
experienced] or never taken [treatment-naive] HIV 
treatment previously [354]. The efficiency and 
toxicity levels of DTG are studied during various 
clinical trials and proved to be safer in both treat-
ment naïve and experienced patients [355]. 
 Phase-I clinical trial studies were carried out on 
34 healthy volunteers and various kidney parame-
ters like glomerular filtration rate, effective renal 
plasma flow, and creatinine clearance were evalu-
ated [356]. The study of DTG over a period of 14 
days revealed that the dose of DTG [50 mg] once 
or twice daily had no prominent effect on GFR as 
compared with placebo. This study demonstrated a 
reversible increase in the creatinine to the non-
pathological levels. The increased creatinine levels 
are attributed to the inhibition of the organic cation 
transporter protein 2, specifically in the proximal 
renal tubule of a nephron. 
 Letendre et al. in 2013 studied TDM of DTG in 
the CSF of 12 ARV-naive HIV-infected patients 
getting DTG 50 mg daily co-administered with 
ABC/3TC regimen [357]. The overall spread of 
DTG in the CSF was just like the unbound DTG in 
blood plasma at week 2 [mean CSF DTG = 16.2 
ng/ml, mean plasma unbound DTG = 16.8 ng/ml] 
and at week 16 [mean CSF DTG = 12.6 ng/ml, 
mean plasma unbound DTG = 23 ng/ml]. Moreo-
ver, the spread of DTG in the CSF for all patients 
at week 16 ranged from 18 to 90-fold higher than 
the in vitro IC50 for wild-type virus [0.2 ng/ml] 
[357, 358]. These studies illustrated that the DTG 
can pass freely across the blood–brain barrier. 
 In a phase-III non-inferiority single trial carried 
out on 833 patients, the adequacy of DTG 50 mg 
once daily co-administered with ABC/3TC com-
pared with EFV/TDF and TDF/FTC once daily 
was carried out [359]. The study revealed that 
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DTG regimen was statistically better to the 
EFV/TDF and TDF/FTC combinations [359]. 
 At clinically relevant concentration, DTG nei-
ther induced nor inhibited CYP or UGT isoen-
zymes [360]. The interaction potential of NRTIs 
with DTG is low as NRTIs do not undergo hepatic 
transformation following CYP metabolic pathway 
[361]. EFV, when co-administered with DTG may 
reduce DTG plasma concentration due to its ability 
to induce /inhibit CYP2B6 or UGT1A1 isoen-
zymes respectively. CYP2B6 and UGT1A1 are the 
major enzymes which metabolize the DTG and 
hence TDM of DTG is essential when co-
administered with EFV [362]. 
 PIs are known UGT1A1 inhibitors. ATV being 
one of them, possesses the ability to enhance DTG 
plasma concentrations. Conversely, RTV is a well-
known inducer of the UGT1A1 pathway and hence 
has the ability to reduce DTG plasma concentra-
tions [363]. DRV and LPV are well-known inhibi-
tors of the CYP3A4 pathway and hence may en-
hance DTG plasma concentrations [364]. This 
ATV interaction also suggests that DTG is a good 
candidate for the TDM when co-administered and 
boosted with PI’s. 
 To help further understand the DTG plasma 
pharmacokinetics, Bennetto-hood et al. have de-
veloped assays for DTG using an LC–MS/MS 
whereas Charbe et al. and Cozzi et al. developed 
simultaneous HPLC-UV assay method for the 
quantification of DTG [191, 365, 366]. Currently, 
one other assay developed by Grégoire et al. 
showed simultaneous determination of the plasma 
concentration of DTG and RPV using deuterated-
internal standards [189]. 
CONCLUSION 
 This review is aimed at focusing on the role of 
liquid chromatographic techniques in TDM of 
ARVs and to give a comprehensive literature sur-
vey of the various ARV assays methods. This re-
view also highlights the advancement of the chro-
matographic techniques beginning from the 
HPLC-UV to the more advanced technique like 
UPLC-MS/MS. TDM is essential to ensure adher-
ence, observe viral resistance and to personalise 
ARV dose regimens. Analytical methods like im-
munoassays and liquid chromatography with de-
tectors like UV, PDA, Florescent, MS, MS/MS 
and UPLC-MS/MS have immensely contributed to 
the clinical outcome of the ARV therapy. Assay 
methods are not only helping physicians in limit-
ing the side effects and drug interaction but also 
assisting in monitoring the patient’s compliance. 
 Literature survey revealed that HPLC has been 
the most widely used system irrespective of the 
availability of more sensitive chromatographic 
technique like UPLC. Because of smaller particle-
sized of stationary phase, shorter column length 
with higher flow rates under high pressure, UPLC 
offers more advantage in terms of efficiency. With 
UPLC, it is now possible to develop more resolved 
methods. Resolved peaks per unit time are higher 
with UPLC which ultimately enhance the data 
quality. The main focus of any research institute or 
of the pharmaceutical industry is to reduce the R & 
D cost and time. Quality data in a shorter time can 
help the industry to save on the method develop-
ment cost. As the UPLC column size is shorter, the 
re-equilibrium time is also short which ultimately 
save on solvents. The only disadvantage of UPLC 
is the higher price of the instrument and reduced 
column life because of the increased back pres-
sure. But the faster separation, reduced solvent 
consumption, and better resolution can counterbal-
ance the disadvantages. Seeing the advantages of 
UPLC, in near future, it is quite possible that 
methods developed on HPLC will be transferred 
on to the UPLC. It has been also revealed that UV 
is commonly used as a detector with HPLC. If the 
sample is adequate, UV detector assures the detec-
tion of all the UV-absorbing components. Over a 
certain period of time, most researchers preferred 
UV detectors with RP-HPLC techniques due to its 
consistency and sensitivity. However, due to the 
limitations associated with HPLC-UV (e.g in-
creased solvents utilization and lack of reproduci-
bility), more sensitive detectors like MS or MS/ 
MS are in demand. These detectors have gained 
more popularity owing to their enhanced sensitiv-
ity, specificity and shorter analysis time. LC–
MS/MS plays a significant role in TDM of HIV 
drugs in different matrices such as plasma, urine, 
PBMCs, CSF, and hair. It is the most preferred 
alternative to immunoassays and HPLC-UV tech-
nique due to its advantage of simultaneous estima-
tion of the number of drugs in picomol concentra-
tions. 
 Although matrix effect is the challenge in 
validation of HPLC-MS assay methods, proper 
sample preparation and use of appropriate chroma-
tographic technique and internal standard give 
near errorless result. In the literature review, it is 
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also observed that most of the ARV drugs are ei-
ther water-soluble or are soluble in polar solvents 
like methanol, ethanol or DMSO which perfectly 
fits in the basic requirement of the method devel-
opments on RP-HPLC. 
 Advancement in the column and pump technol-
ogy leads to the development of the automatic 
rapid UPLC-MS/MS system. With the advantage 
of higher speed, sensitivity, reproducibility, and 
specificity over HPLC, UPLC can be used to si-
multaneously separate and determine multicompo-
nent ARVs in different matrices. UPLC with mass 
detectors clearly has huge prospective for metabo-
lite detections and is becoming an important tool 
in clinical pharmacology laboratories. Analytical 
and clinical laboratories will be continuously 
tested with blood samples containing a wide range 
of ARVs in extremely low concentrations. Hence, 
the highly sensitive and specific identification 
methods like LC–MS/MS and UPLC-MS/MS ap-
pear to be the technique of the preferred technique 
of future. 
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